<!DOCTYPE html><html lang="en" class="__variable_6d343d __variable_49a339"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/26d4368bf94c0ec4-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/_next/static/media/36966cca54120369-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" as="image" href="/logo.svg" fetchPriority="high"/><link rel="stylesheet" href="/_next/static/css/f5dc3b4b8467221e.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-04cc3a393714a88b.js"/><script src="/_next/static/chunks/fd9d1056-4b87d5bb1aa946b3.js" async=""></script><script src="/_next/static/chunks/23-7a13f39f0e990758.js" async=""></script><script src="/_next/static/chunks/main-app-9c6ab80fd9a4d8e3.js" async=""></script><script src="/_next/static/chunks/231-9e11bdfe3b664aec.js" async=""></script><script src="/_next/static/chunks/app/sectors/%5Bsector%5D/page-69ab854d38ad1414.js" async=""></script><script src="/_next/static/chunks/896-78f6f35c40d7ae60.js" async=""></script><script src="/_next/static/chunks/app/layout-24f8abeacb8025a3.js" async=""></script><link rel="icon" href="/logo.svg" type="image/svg+xml"/><title>health care sector stocks on the ASX | trends &amp; top performers | ASX Desk</title><meta name="description" content="Explore ASX health care stocks, sector trends, and leading performers with AI-generated insights."/><link rel="canonical" href="https://asxdesk.com/sectors/health%20care/"/><meta property="og:title" content="health care sector stocks on the ASX | trends &amp; top performers"/><meta property="og:description" content="Explore ASX health care stocks, sector trends, and leading performers with AI-generated insights."/><meta property="og:url" content="https://asxdesk.com/sectors/health%20care/"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="ASX Desk"/><meta name="twitter:description" content="Australia&#x27;s AI-powered ASX stock research platform delivering instant analysis, sector insights, and SEO-optimized company profiles."/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-78c92fac7aa8fdd8.js" noModule=""></script></head><body class="min-h-screen bg-ink-900 text-slate-100"><div class="grid-glow min-h-screen"><header class="sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur"><div class="mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8"><a class="flex items-center gap-3" href="/"><img alt="ASX Desk" fetchPriority="high" width="140" height="40" decoding="async" data-nimg="1" class="h-10 w-auto" style="color:transparent" src="/logo.svg"/><span class="hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline">Research Terminal</span></a><nav class="hidden items-center gap-6 text-sm text-slate-300 md:flex"><a class="transition hover:text-white" href="/">Home</a><a class="transition hover:text-white" href="/screener/">Screener</a><a class="transition hover:text-white" href="/sectors/materials/">Sectors</a><a class="transition hover:text-white" href="/news/">News</a><a class="transition hover:text-white" href="/compare/BHP-vs-RIO/">Compare</a><a class="transition hover:text-white" href="/about/">About</a></nav><div class="hidden items-center gap-3 md:flex"><div class="relative"><div class="flex items-center rounded-full border border-white/10 bg-ink-900/70 px-3 py-1.5 focus-within:border-blue-500/60 transition"><svg class="h-4 w-4 shrink-0 text-slate-500" fill="none" stroke="currentColor" viewBox="0 0 24 24" stroke-width="2"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35" stroke-linecap="round"></path></svg><input type="text" placeholder="Search ticker…" class="ml-2 w-36 bg-transparent text-xs text-white placeholder:text-slate-500 focus:outline-none lg:w-44" value=""/></div></div><button class="rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20">Premium Research</button><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400">Open Account</button></div></div><div class="flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden"><div class="flex-1"><div class="relative"><div class="flex items-center rounded-full border border-white/10 bg-ink-900/70 px-3 py-1.5 focus-within:border-blue-500/60 transition"><svg class="h-4 w-4 shrink-0 text-slate-500" fill="none" stroke="currentColor" viewBox="0 0 24 24" stroke-width="2"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35" stroke-linecap="round"></path></svg><input type="text" placeholder="Search ticker…" class="ml-2 w-36 bg-transparent text-xs text-white placeholder:text-slate-500 focus:outline-none lg:w-44" value=""/></div></div></div><a class="shrink-0 text-xs text-blue-300" href="/screener/">Screener</a></div></header><main class="mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8"><div class="space-y-10"><section class="glass-card rounded-2xl p-6"><p class="text-xs uppercase tracking-[0.3em] text-blue-300">Sector</p><h1 class="mt-2 font-display text-3xl font-semibold">health care<!-- --> Stocks</h1><p class="mt-4 text-sm text-slate-300">Deep-dive coverage on ASX <!-- -->health care<!-- --> leaders, thematic trends, and relative performance signals. Our AI engine tracks earnings momentum, capital allocation, and sector rotation.</p><div class="mt-5 flex flex-wrap gap-3 text-xs text-slate-400"><span class="rounded-full border border-white/10 px-3 py-1">166<!-- --> stocks tracked</span><span class="rounded-full border border-white/10 px-3 py-1">Updated daily</span><span class="rounded-full border border-white/10 px-3 py-1">AI sector heatmaps</span></div></section><section class="grid gap-6 lg:grid-cols-2"><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-lg font-semibold">Top Performers</h2><div class="mt-4 space-y-3"><p class="text-sm text-slate-400">Performance data is still being compiled for this sector.</p></div></div><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-lg font-semibold">Worst Performers</h2><div class="mt-4 space-y-3"><p class="text-sm text-slate-400">Performance data is still being compiled for this sector.</p></div></div></section><section class="space-y-6"><h2 class="font-display text-2xl font-semibold">All <!-- -->health care<!-- --> Coverage</h2><div class="grid gap-6 md:grid-cols-2"><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CSL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CSL<span class="ml-2 text-sm text-slate-400">CSL Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->181.24</p><p class="text-xs font-semibold text-red-400">-27.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$88.2B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PNV/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PNV<span class="ml-2 text-sm text-slate-400">Polynovo Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.99</p><p class="text-xs font-semibold text-red-400">-13.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$670M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/1AD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">1AD<span class="ml-2 text-sm text-slate-400">Adalta Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-25.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$11M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/1AI/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">1AI<span class="ml-2 text-sm text-slate-400">Algorae Pharmaceuticals Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.02</p><p class="text-xs font-semibold text-emerald-400">380.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Algorae Pharmaceuticals is an Australian drug discovery company utilizing its proprietary artificial intelligence platform, AlgoraeOS, to identify and develop novel therapeutic treatments. The company focuses on creating drug candidates for conditions with unmet medical needs, including dementia, cardiovascular disease, and Meniere&#x27;s disease. Its business model is centered on leveraging AI to accelerate the traditionally lengthy and costly process of pharmaceutical research and development.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$34M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/4DX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">4DX<span class="ml-2 text-sm text-slate-400">4Dmedical Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->3.15</p><p class="text-xs font-semibold text-emerald-400">1066.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">4Dmedical Limited specializes in developing and commercializing state-of-the-art respiratory imaging technology, notably its XV Lung Ventilation Analysis Software (XV LVAS). This non-invasive technology provides quantitative and visual assessments of regional lung function, aiming to improve the diagnosis and management of various respiratory conditions. The company primarily operates in Australia and is aggressively expanding its presence in the large US healthcare market.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$1.9B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ACL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ACL<span class="ml-2 text-sm text-slate-400">Australian Clinical Labs Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->2.73</p><p class="text-xs font-semibold text-red-400">-8.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Australian Clinical Labs (ACL) is one of Australia&#x27;s largest private pathology providers, offering a comprehensive range of services including blood tests, tissue analysis, and genetic testing. The company operates an extensive network of accredited laboratories and collection centres across the country, servicing general practitioners, medical specialists, and hospitals. ACL focuses on delivering accurate and timely diagnostic services to support patient care and clinical decision-making.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$515M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ACR/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ACR<span class="ml-2 text-sm text-slate-400">Acrux Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.02</p><p class="text-xs font-semibold text-red-400">-33.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Acrux Limited is an Australian pharmaceutical company specialising in the development and commercialisation of topical and transdermal pharmaceutical products. Its flagship product, Estradiol Topical Solution (Evamist/Sprayon/Gynelle), is approved for treating moderate to severe vasomotor symptoms associated with menopause and is commercialised globally through licensing partnerships. The company leverages its proprietary formulation expertise to develop novel therapeutic solutions.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$6M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ACW/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ACW<span class="ml-2 text-sm text-slate-400">Actinogen Medical Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.04</p><p class="text-xs font-semibold text-emerald-400">40.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Actinogen Medical Limited (ASX: ACW) is an Australian clinical-stage biotechnology company focused on developing treatments for neurological and psychiatric disorders. Its lead compound, Xanamem, is an orally administered small molecule designed to inhibit the enzyme 11β-HSD1, which plays a role in cognitive dysfunction associated with diseases like Alzheimer&#x27;s and depression. The company operates globally with its primary research and development activities in Australia and the US.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$153M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ADR/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ADR<span class="ml-2 text-sm text-slate-400">Adherium Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-54.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Adherium Limited develops digital health solutions focused on improving medication adherence and outcomes for chronic respiratory diseases, primarily asthma and COPD. Their flagship Hailie® platform integrates connected medical devices, such as smart inhalers, with software and data analytics to monitor medication usage and provide patient insights. The company aims to partner with pharmaceutical companies and healthcare providers globally to commercialise its technology.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$12M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ADO/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ADO<span class="ml-2 text-sm text-slate-400">Anteotech Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-emerald-400">8.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Anteotech Ltd is an Australian surface chemistry technology company developing and commercialising its proprietary &#x27;Anteo&#x27; platform. The company operates across two high-growth sectors: the energy division focuses on &#x27;AnteoX&#x27;, a high-performance binder additive for lithium-ion batteries, while the life sciences division leverages its &#x27;Anteobind&#x27; technology to improve the performance of diagnostic tests and other medical applications.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$40M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AFP/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AFP<span class="ml-2 text-sm text-slate-400">Aft Pharmaceuticals Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->3.10</p><p class="text-xs font-semibold text-emerald-400">34.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Aft Pharmaceuticals Limited is a New Zealand-based specialty pharmaceutical company focused on the development, licensing, and distribution of a broad range of innovative over-the-counter (OTC) and prescription products. Its flagship product, Maxigesic, a proprietary pain relief medication, is central to its international expansion strategy across Australia, New Zealand, Asia, Europe, and the US.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$325M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AGN/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AGN<span class="ml-2 text-sm text-slate-400">Argenica Therapeutics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.29</p><p class="text-xs font-semibold text-red-400">-61.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Argenica Therapeutics Limited (ASX: AGN) is an Australian biotechnology company focused on developing novel therapeutics for neurological conditions, primarily stroke. Their lead product candidate, ARG-007, aims to reduce brain tissue damage and improve patient outcomes after an ischaemic stroke, addressing a significant unmet medical need.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$37M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AHC/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AHC<span class="ml-2 text-sm text-slate-400">Austco Healthcare Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.38</p><p class="text-xs font-semibold text-emerald-400">28.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Austco Healthcare Limited (ASX: AHC) is a global developer and supplier of critical communication and nurse call technology solutions for the healthcare sector. The company primarily serves hospitals, aged care facilities, and other healthcare environments, providing advanced IP-based nurse call systems and integrated communication platforms. AHC operates internationally with a significant presence across Australia, North America, the UK, and the Middle East.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$139M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AHE/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AHE<span class="ml-2 text-sm text-slate-400">Adheris Health Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.02</p><p class="text-xs font-semibold text-emerald-400">0.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Adheris Health Limited (ASX: AHE) operates within the health care equipment and services sector in Australia, focusing on patient engagement solutions through its proprietary platform, aiding in medication adherence. Primarily serving healthcare providers and pharmaceutical companies, AHE’s key offerings include personalized patient support programs. Headquartered in Australia, it serves the APAC region.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$13M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AHX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AHX<span class="ml-2 text-sm text-slate-400">Apiam Animal Health Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.87</p><p class="text-xs font-semibold text-emerald-400">123.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Apiam Animal Health Limited is a leading provider of veterinary services, operating a network of clinics predominantly across regional and rural Australia. The company offers a comprehensive range of veterinary care for companion animals, equine, and livestock, along with related products and services.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$160M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ALA/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ALA<span class="ml-2 text-sm text-slate-400">Arovella Therapeutics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.09</p><p class="text-xs font-semibold text-emerald-400">17.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Arovella Therapeutics Limited (ALA) is an Australian biotechnology company focusing on developing innovative therapies, particularly in the oncology and rare diseases spaces. Operating primarily out of Australia, ALA leverages cutting-edge research to bring potential life-changing treatments to global markets. Key products/services include its proprietary drug candidates in various clinical trial phases.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$114M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ALC/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ALC<span class="ml-2 text-sm text-slate-400">Alcidion Group Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.10</p><p class="text-xs font-semibold text-emerald-400">28.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Alcidion Group Limited is a healthcare technology company that develops and markets software solutions designed to improve patient care and operational efficiency in hospitals and healthcare organizations. Operating primarily in the UK, Australia, and New Zealand, their key products include the Miya Precision platform, which offers electronic medication management (Better Meds), patient flow, and clinical decision support systems.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$148M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AN1/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AN1<span class="ml-2 text-sm text-slate-400">Anagenics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-25.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Anagenics Limited (ASX: AN1) is an Australian biotechnology company focused on developing and commercialising solutions for hair loss and hair regrowth. Operating primarily in the health care sector, the company aims to address unmet needs in the global hair care market through scientific research and proprietary product development.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$3M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ANR/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ANR<span class="ml-2 text-sm text-slate-400">Anatara Lifesciences Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-emerald-400">71.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Anatara Lifesciences Ltd (ASX: ANR) is an Australian biotechnology company focused on developing and commercializing novel treatments for gastrointestinal diseases in humans and animals. Operating primarily from Australia, its key product is Anatara&#x27;s CIC therapy for carbohydrate malabsorption. The company also explores veterinary applications.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$3M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ANN/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ANN<span class="ml-2 text-sm text-slate-400">Ansell Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->32.37</p><p class="text-xs font-semibold text-red-400">-4.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Ansell Limited is a global leader in providing superior health and safety protection solutions that enhance human well-being. The company designs, develops, and manufactures a wide range of protection solutions, primarily surgical, examination, and industrial gloves, as well as protective body suits. Ansell operates globally with a strong presence in both the healthcare and industrial sectors, supported by well-known brands like Gammex, Microflex, and AlphaTec.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$4.7B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ARX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ARX<span class="ml-2 text-sm text-slate-400">Aroa Biosurgery Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.67</p><p class="text-xs font-semibold text-emerald-400">57.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Aroa Biosurgery Limited (ASX: ARX) develops and commercializes surgical biomaterials in the global healthcare sector, focusing on advanced wound care and surgical procedures. Based in Auckland, New Zealand, with listing on the ASX, its key products include Absorbable Puteon and other bioactive surgical implants. Operating primarily in Australia, New Zealand, and expanding into North America.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$235M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AT1/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AT1<span class="ml-2 text-sm text-slate-400">Atomo Diagnostics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.04</p><p class="text-xs font-semibold text-emerald-400">135.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Atomo Diagnostics Limited (ASX: AT1) is an Australian medical device company specialising in the design, manufacture, and commercialisation of user-friendly rapid diagnostic test (RDT) devices. Its patented AtomoRapid platform simplifies blood-based point-of-care and self-test applications, aiming to improve testing accuracy and accessibility for various infectious diseases globally.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$34M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ATH/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ATH<span class="ml-2 text-sm text-slate-400">Alterity Therapeutics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-emerald-400">0.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Alterity Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. Headquartered in Melbourne, Australia, the company&#x27;s lead candidate, ATH434, is a small molecule drug designed to treat Multiple System Atrophy (MSA) and other Parkinsonian disorders by restoring the brain&#x27;s normal iron balance. Alterity is advancing ATH434 through global clinical trials to address the high unmet medical need in these conditions.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$87M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ATX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ATX<span class="ml-2 text-sm text-slate-400">Amplia Therapeutics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.13</p><p class="text-xs font-semibold text-emerald-400">78.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Amplia Therapeutics Limited is an Australian clinical-stage biotechnology company focused on developing novel treatments for cancer and fibrosis. The company is advancing small molecule inhibitors, including AMP945 (a FAK inhibitor) and AMP880 (a p38 MAPK inhibitor), with lead programs targeting pancreatic cancer and idiopathic pulmonary fibrosis.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$67M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AVE/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AVE<span class="ml-2 text-sm text-slate-400">Avecho Biotechnology Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-emerald-400">100.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Avecho Biotechnology Limited (ASX: AVE) operates in Australia, specializing in the development of innovative therapeutic products for unmet medical needs. Focused on proprietary formulations and delivery technologies for existing drugs, improving efficacy and patient outcomes. Key product pipeline: Novel formulations for pain management and neurology.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$33M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AVH/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AVH<span class="ml-2 text-sm text-slate-400">Avita Medical Inc.</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->1.14</p><p class="text-xs font-semibold text-red-400">-58.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Avita Medical Inc. is a regenerative medicine company developing and commercialising the RECELL System, a medical device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of a patient’s own skin. This innovative technology is primarily used for the treatment of acute thermal burns, with expanding applications in vitiligo and reconstructive procedures, and its commercial operations are predominantly focused in the United States.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$186M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AVR/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AVR<span class="ml-2 text-sm text-slate-400">Anteris Technologies Global Corp.</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->7.80</p><p class="text-xs font-semibold text-emerald-400">20.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Anteris Technologies Global Corp. (ASX: AVR) is an Australian-based medical device company focused on structural heart disease. They are developing the DurAVR™ Transcatheter Aortic Valve Replacement (TAVR) system, which incorporates their proprietary ADAPT® anti-calcification tissue technology designed to enhance valve durability and improve patient outcomes for severe aortic stenosis.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$813M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AYA/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AYA<span class="ml-2 text-sm text-slate-400">Artrya Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->3.38</p><p class="text-xs font-semibold text-emerald-400">350.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Artrya Limited is an Australian medical technology company that develops and commercializes AI-powered software for the diagnosis of coronary artery disease. Its flagship product, Salix, analyzes cardiac CT scans to identify stenosis and vulnerable plaque, aiming to improve diagnostic accuracy and prevent heart attacks. The company targets cardiologists, radiologists, and hospitals globally, with key regulatory approvals in Australia, Europe, and the USA.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$547M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/BB1/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">BB1<span class="ml-2 text-sm text-slate-400">Blinklab Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.94</p><p class="text-xs font-semibold text-emerald-400">144.2<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Blinklab Limited (ASX: BB1) is a Australian health tech company, operating in the health care equipment and services sector. Specific to the Australian market, it develops innovative, non-invasive diagnostic devices for early detection of ophthalmological conditions, leveraging AI-driven analysis. Key product is &#x27;EyeSightAI&#x27;, targeting the Australian healthcare system and private clinics.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$124M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/BDX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">BDX<span class="ml-2 text-sm text-slate-400">Bcal Diagnostics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.12</p><p class="text-xs font-semibold text-emerald-400">12.2<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Bcal Diagnostics Limited (ASX: BDX) is an Australian biotechnology company focused on developing a novel, non-invasive blood test for the early detection of breast cancer, named the Bcal™ test. Leveraging specific lipid biomarkers, their technology aims to provide a more accessible and accurate screening tool, initially targeting the Australian market with global commercialisation ambitions.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$42M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/BIT/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">BIT<span class="ml-2 text-sm text-slate-400">Biotron Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.00</p><p class="text-xs font-semibold text-red-400">-14.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Biotron Limited is a clinical-stage biotechnology company based in Australia, focused on the development of novel antiviral drugs targeting a range of significant diseases. Its lead compound, BIT225, is in clinical development for the treatment of HIV-1, aiming to eradicate the virus from reservoirs in the body. The company&#x27;s research also extends to other viruses, including Hepatitis C and, more recently, coronaviruses.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$8M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/BMT/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">BMT<span class="ml-2 text-sm text-slate-400">Beamtree Holdings Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.18</p><p class="text-xs font-semibold text-red-400">-23.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Beamtree is a healthcare technology company specialising in clinical decision support and health data analytics. It provides software-as-a-service (SaaS) solutions, such as its PICQ and RippleDown platforms, to hospitals and health services to automate clinical record classification, improve data quality, and support diagnostic decisions. The company primarily operates in Australia with a growing international presence, aiming to improve administrative efficiency and patient outcomes.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$49M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/BP8/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">BP8<span class="ml-2 text-sm text-slate-400">Bph Global Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.00</p><p class="text-xs font-semibold text-red-400">-14.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Bph Global Ltd (ASX: BP8) is an Australian-based biotechnology company focused on the early-stage research and development of novel therapeutic compounds. The company primarily targets unmet medical needs within specific disease areas, aiming to advance promising drug candidates through pre-clinical and early clinical trial phases. BP8 operates as a lean R&amp;D entity, leveraging scientific partnerships to progress its pipeline.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$4M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/BOT/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">BOT<span class="ml-2 text-sm text-slate-400">Botanix Pharmaceuticals Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.12</p><p class="text-xs font-semibold text-red-400">-73.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Botanix Pharmaceuticals is a clinical-stage dermatology company focused on developing and commercializing treatments for common skin conditions. Its lead product, Sofdra™ (sofpironium bromide gel, 12.45%), recently received FDA approval for the treatment of excessive underarm sweating (primary axillary hyperhidrosis). The company leverages its proprietary Permetrex™ skin delivery technology for its product pipeline, which also includes candidates for rosacea and acne.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$227M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CAN/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CAN<span class="ml-2 text-sm text-slate-400">Cann Group Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-68.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Cann Group Limited is a pioneering Australian medicinal cannabis company focused on the breeding, cultivation, and manufacturing of cannabis for medical and research purposes. Operating primarily from its large-scale, state-of-the-art facility in Mildura, Victoria, the company produces a range of GMP-certified dried flower and oil-based products for supply to patients in Australia and for export markets.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$13M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CBL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CBL<span class="ml-2 text-sm text-slate-400">Control Bionics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.06</p><p class="text-xs font-semibold text-emerald-400">31.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Control Bionics Limited (ASX: CBL) is a healthcare equipment and services company operating in Australia, focusing on the development and distribution of innovative assistive technologies. Key products include customizable, speech-generating devices for individuals with severe speech and language impairments. Founded in 2016 and listed on the ASX in December 2020.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$25M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CC5/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CC5<span class="ml-2 text-sm text-slate-400">Clever Culture Systems Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.03</p><p class="text-xs font-semibold text-emerald-400">107.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Clever Culture Systems Limited (CC5) is an Australian healthcare equipment and services company developing innovative cell culture solutions for the biotechnology and pharmaceutical industries. Operating primarily in Australia, with potential expansion to APAC regions, its key product is the Clever Culture SystemTM, designed to enhance cell growth and efficiency in research and production settings.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$61M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CGS/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CGS<span class="ml-2 text-sm text-slate-400">Cogstate Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->2.16</p><p class="text-xs font-semibold text-emerald-400">55.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Cogstate Ltd (ASX: CGS) is a health technology company providing innovative brain health solutions, including cognitive testing and assessment tools, operating globally with a strong presence in Australia and the USA. Key products include its proprietary cognitive assessment technologies used in clinical trials, research, and healthcare. Its platform is utilized by pharmaceutical companies, academic institutions, and healthcare providers to measure cognitive function in various neurological and psychiatric conditions.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$374M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CHM/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CHM<span class="ml-2 text-sm text-slate-400">Chimeric Therapeutics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.00</p><p class="text-xs font-semibold text-red-400">-60.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Chimeric Therapeutics is a clinical-stage cell therapy company focused on developing and commercialising novel treatments for cancer. The company&#x27;s pipeline includes both autologous and allogeneic (&#x27;off-the-shelf&#x27;) CAR T and CAR NK cell therapies. Its lead assets are CHM 1101 (CLTX CAR T) for glioblastoma and CHM 2101 (CDH17 CAR T) for gastrointestinal cancers, with clinical trials being conducted in the United States.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$9M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CMB/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CMB<span class="ml-2 text-sm text-slate-400">Cambium Bio Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.59</p><p class="text-xs font-semibold text-emerald-400">93.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Cambium Bio Limited is an Australian clinical-stage biotechnology company focused on developing novel regenerative medicine therapies. Its lead program is centered on a proprietary cell-based treatment for osteoarthritis, aiming to repair damaged cartilage and reduce inflammation. The company&#x27;s operations are primarily focused on preclinical research and advancing its lead candidate into early-stage human clinical trials.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$14M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CMP/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CMP<span class="ml-2 text-sm text-slate-400">Compumedics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.35</p><p class="text-xs font-semibold text-emerald-400">1.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Compumedics Limited is an Australian medical device company specializing in the development and sale of diagnostic technology for sleep disorders, neurology, and brain research. The company operates globally, with key products including laboratory-based and wearable sleep monitoring systems (Somfit), neuro-diagnostic equipment (Neuroscan), and advanced magnetoencephalography (MEG) brain imaging systems.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$75M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/COH/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">COH<span class="ml-2 text-sm text-slate-400">Cochlear Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->258.74</p><p class="text-xs font-semibold text-red-400">-1.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Cochlear Limited is a global medical device company that designs, manufactures, and supplies implantable hearing solutions, including cochlear implants, bone conduction implants, and acoustic implants. Operating worldwide, the company helps individuals with moderate to profound hearing loss, maintaining a dominant market position in its specialized field.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$17.0B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/COV/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">COV<span class="ml-2 text-sm text-slate-400">Cleo Diagnostics Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.60</p><p class="text-xs font-semibold text-emerald-400">71.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Cleo Diagnostics Ltd (COV) is an ASX-listed life sciences company focused on developing diagnostic solutions, primarily operating in Australia. Its key products/services include novel point-of-care and lab-based diagnostic technologies for infectious diseases. COV is in the pre-commercialization phase, with a focus on R&amp;D.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$86M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CQT/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CQT<span class="ml-2 text-sm text-slate-400">Conneqt Health Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.04</p><p class="text-xs font-semibold text-emerald-400">32.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Conneqt Health Limited is an Australian digital health company providing an integrated platform that connects consumers, healthcare providers, and payers. Its core products include MyHealth1st, an online healthcare booking marketplace, and Visionflex, a telehealth hardware and software solution. The company aims to improve access to healthcare and streamline administrative processes for clinics, governments, and corporate clients across Australia.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$28M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CSX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CSX<span class="ml-2 text-sm text-slate-400">Cleanspace Holdings Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.65</p><p class="text-xs font-semibold text-emerald-400">39.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">CleanSpace Holdings Limited designs, manufactures, and sells advanced respiratory protection equipment. The company&#x27;s core products are compact and lightweight Powered Air Purifying Respirators (PAPRs) used by healthcare professionals and industrial workers globally to protect against airborne contaminants and infectious diseases.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$51M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CTE/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CTE<span class="ml-2 text-sm text-slate-400">Cryosite Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->1.10</p><p class="text-xs font-semibold text-emerald-400">38.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Cryosite Limited is an Australian company specializing in two main areas: private cord blood and tissue banking for families, and outsourced clinical trial logistics, biological storage, and cryo-preservation services for the biotechnology and pharmaceutical industries. Operating from its TGA-licensed facility in Sydney, the company provides critical temperature-controlled storage and distribution solutions for high-value biological materials.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$54M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CTQ/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CTQ<span class="ml-2 text-sm text-slate-400">Careteq Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-26.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Careteq Limited (ASX: CTQ) is a health care company focused on developing and providing innovative health care equipment and services, operating primarily in Australia. Key products/services include personalized aged care solutions and assistive technology. With a specific focus on the aging population, CTQ offers smart home automation systems for elderly care facilities.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$3M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CU6/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CU6<span class="ml-2 text-sm text-slate-400">Clarity Pharmaceuticals Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->2.89</p><p class="text-xs font-semibold text-emerald-400">37.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Clarity Pharmaceuticals is an Australian radiopharmaceutical company focused on developing innovative diagnostic and therapeutic products for cancer using copper isotopes. Its proprietary &#x27;Theranostics&#x27; platform targets cancers such as prostate cancer (with SAR-bisPSMA) and neuroblastoma (with SARTATE), with lead candidates currently in advanced global clinical trials.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$1.0B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CVB/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CVB<span class="ml-2 text-sm text-slate-400">Curvebeam Ai Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.08</p><p class="text-xs font-semibold text-red-400">-36.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Curvebeam Ai Limited (ASX: CVB) is a medical technology company specializing in the design and manufacture of weight-bearing CT imaging systems for extremities. Their proprietary systems, such as the HiRise and PedCat, integrate AI capabilities to provide high-resolution 3D images that aid in the diagnosis and treatment of orthopedic and podiatric conditions. Operating globally, the company aims to improve clinical outcomes through advanced diagnostic imaging.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$38M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CUV/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CUV<span class="ml-2 text-sm text-slate-400">Clinuvel Pharmaceuticals Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->11.73</p><p class="text-xs font-semibold text-emerald-400">2.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Clinuvel Pharmaceuticals is a global biopharmaceutical company focused on developing and commercialising treatments for patients with severe genetic and skin disorders. Its lead product, SCENESSE® (afamelanotide), is the world&#x27;s first systemic photoprotective drug approved for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP) across Europe, the USA, and Australia. The company is actively pursuing the expansion of SCENESSE® into new indications with larger patient populations, such as vitiligo.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$592M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CYC/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CYC<span class="ml-2 text-sm text-slate-400">Cyclopharm Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.93</p><p class="text-xs font-semibold text-red-400">-19.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Cyclopharm Limited (ASX: CYC) is an Australian-based company specializing in nuclear medicine products. Its flagship product, TechneGas (marketed as TechneLite in some regions), is a lung ventilation imaging agent used primarily for the diagnosis of pulmonary embolism. The company operates globally, with a significant focus on commercialising TechneGas in major markets like the United States following recent regulatory approvals.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$107M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CYP/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CYP<span class="ml-2 text-sm text-slate-400">Cynata Therapeutics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.34</p><p class="text-xs font-semibold text-emerald-400">86.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Cynata Therapeutics Limited (ASX: CYP) is an Australian biotechnology company focused on developing innovative cellular therapies for serious diseases using its proprietary Cell Control Technology. Operating primarily in the Australian market with research collaborations globally, its key product in development is rCTRM, a mesenchymal stromal cell therapy for acute respiratory distress syndrome (ARDS) and other inflammatory conditions.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$83M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/DOC/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">DOC<span class="ml-2 text-sm text-slate-400">Doctor Care Anywhere Group Plc</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.14</p><p class="text-xs font-semibold text-emerald-400">52.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Doctor Care Anywhere is a UK-founded digital health company providing virtual GP consultations and other telehealth services. It operates primarily on a B2B2C model, partnering with major insurers, like AXA Health, and corporate clients to offer its 24/7 platform to their members and employees. The company&#x27;s core service allows patients to book and attend video or phone appointments with doctors for diagnostics, prescriptions, and specialist referrals.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$59M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/DVL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">DVL<span class="ml-2 text-sm text-slate-400">Dorsavi Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.04</p><p class="text-xs font-semibold text-emerald-400">500.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Dorsavi Ltd (ASX: DVL) is an Australian-based company that develops wearable sensor technology and software solutions for analyzing human movement. Their proprietary technology provides objective data for injury prevention, performance enhancement, and clinical rehabilitation across elite sports, occupational health, and healthcare sectors, operating globally.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$43M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/DXB/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">DXB<span class="ml-2 text-sm text-slate-400">Dimerix Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.52</p><p class="text-xs font-semibold text-emerald-400">24.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Dimerix Limited is an Australian clinical-stage biotechnology company focused on developing innovative new therapies for kidney and inflammatory diseases. Its lead candidate, DMX-200, is currently in a global Phase 3 clinical trial for Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney disorder. The company&#x27;s pipeline leverages its proprietary G protein-coupled receptor (GPCR) technology.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$315M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/EBO/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">EBO<span class="ml-2 text-sm text-slate-400">Ebos Group Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->22.15</p><p class="text-xs font-semibold text-red-400">-36.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Ebos Group Limited (EBO) is a leading provider of medical and surgical products and services in Australia and New Zealand. Operating across both countries, EBO supplies a broad range of healthcare solutions including medical equipment, pharmaceuticals, and diagnostic products to hospitals, private practices, and retail pharmacies. A key focus is on distributing products from international manufacturers to the Australasian market.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$4.5B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/EBR/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">EBR<span class="ml-2 text-sm text-slate-400">Ebr Systems Inc.</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.76</p><p class="text-xs font-semibold text-red-400">-56.9<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Ebr Systems is a US-based medical device company developing the world&#x27;s only wireless, inside-the-heart (endocardial) pacing system for cardiac resynchronization therapy (CRT). Their lead product, the WiSE™ system, is designed to treat heart failure patients who have not responded to traditional CRT methods or are unsuitable for them. The company is primarily focused on gaining US Food and Drug Administration (FDA) approval for WiSE, with its pivotal SOLVE-CRT clinical trial being the key value driver.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$347M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ECS/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ECS<span class="ml-2 text-sm text-slate-400">Ecs Botanics Holdings Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-61.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Ecs Botanics Holdings Ltd (ASX: ECS) operates in the Health Care sector, focusing on Pharmaceuticals, Biotechnology, and Life Sciences. Based in Australia, the company specializes in the development and commercialization of cannabinoid-based health products. Key offerings include CBD-infused wellness products and cannabis for medical use, primarily targeting the Australian and New Zealand markets.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$10M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/EMD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">EMD<span class="ml-2 text-sm text-slate-400">Emyria Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.05</p><p class="text-xs font-semibold text-emerald-400">74.2<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Emyria Limited is a data-backed clinical drug development company operating in Australia. It runs a network of specialist medical clinics (Emerald Clinics) that gather proprietary Real-World Evidence from patients using unregistered medicines like cannabinoids. This data is then used to develop its own drug candidates and advance its programs in psychedelic-assisted therapies, most notably an MDMA-assisted therapy program for Post-Traumatic Stress Disorder (PTSD).</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$47M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ENL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ENL<span class="ml-2 text-sm text-slate-400">Enlitic Inc.</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-85.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Enlitic Inc. (ASX: ENL), listed as of December 19, 2023, is a micro-cap Health Care company focused on developing artificial intelligence (AI) driven diagnostic tools for the medical imaging sector, primarily operating in Australia with ambitious global expansion plans. Key products/services include AI-powered imaging analysis software for healthcare providers. Given its early listing stage, specific operational details are limited but the company aims to disrupt traditional diagnostic processes with machine learning algorithms.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$9M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/EMV/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">EMV<span class="ml-2 text-sm text-slate-400">Emvision Medical Devices Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->1.75</p><p class="text-xs font-semibold text-red-400">-17.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Emvision Medical Devices Ltd (ASX: EMV) is an Australian medical device company developing a portable brain scanner based on electromagnetic microwave technology. Their primary focus is on providing rapid and accessible diagnosis of stroke in various settings, from ambulances to remote clinics, aiming to improve patient outcomes through early detection. The company targets global markets for its innovative diagnostic solution.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$168M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ENP/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ENP<span class="ml-2 text-sm text-slate-400">Entropy Neurodynamics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.03</p><p class="text-xs font-semibold text-red-400">-6.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Entropy Neurodynamics Limited (ASX: ENP) is an Australian biotechnology company focused on the research and development of novel therapeutic solutions for complex neurological disorders. Leveraging advanced neurodynamic principles, the company aims to address significant unmet medical needs in areas such as neurodegenerative diseases and neuropsychiatric conditions through its pipeline of proprietary drug candidates.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$52M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/EPI/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">EPI<span class="ml-2 text-sm text-slate-400">Epiminder Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.78</p><p class="text-xs font-semibold text-red-400">-23.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Epiminder Limited (ASX: EPI) is a Australian health tech company providing AI-driven medical reminders and adherence solutions for patients with chronic conditions, operating primarily in the Australian healthcare market. Their key product is the Epiminder Platform, which offers personalized medication reminders and health tracking. As a small-cap company, its operations are focused on the Australian market with potential for expansion into broader APAC regions.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$171M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/EPN/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">EPN<span class="ml-2 text-sm text-slate-400">Epsilon Healthcare Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.03</p><p class="text-xs font-semibold text-emerald-400">37.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Epsilon Healthcare Limited (EPN) was an Australian pharmaceutical company primarily engaged in the cultivation, manufacturing, and distribution of medicinal cannabis products, focusing on B2B and white-label services. Operating a TGA-licensed facility in Southport, Queensland, the company aimed to supply both domestic and international markets. However, the company faced significant financial challenges, leading to its delisting from the ASX on 1 March 2024 following administration.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$11M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/EYE/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">EYE<span class="ml-2 text-sm text-slate-400">Nova Eye Medical Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.17</p><p class="text-xs font-semibold text-emerald-400">70.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Nova Eye Medical Limited (ASX: EYE) develops and markets innovative ocular (eye) care medical devices and services, primarily operating within Australia and expanding into APAC regions. Key products include the iStent device for glaucoma treatment and proprietaryLASIK surgery technologies. Their services extend to ophthalmic clinical trial management and eye care clinics.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$50M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/FCG/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">FCG<span class="ml-2 text-sm text-slate-400">Freedom Care Group Holdings Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.04</p><p class="text-xs font-semibold text-emerald-400">0.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Freedom Care Group Holdings Limited (FCG) is an Australian provider of in-home care services, primarily supporting individuals under the National Disability Insurance Scheme (NDIS) and those requiring aged care. The company aims to empower clients to live independently in their own homes by delivering personalised care plans and support services across various regions in Australia.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$-1</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/FPH/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">FPH<span class="ml-2 text-sm text-slate-400">Fisher &amp; Paykel Healthcare Corporation Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->33.87</p><p class="text-xs font-semibold text-emerald-400">12.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Fisher &amp; Paykel Healthcare is a global leader in designing, manufacturing, and marketing products and systems for use in acute and chronic respiratory care, sleep apnea treatment, and surgical applications. Headquartered in New Zealand and dual-listed on the ASX, the company operates across more than 120 countries, primarily serving hospitals and home care providers worldwide with innovative medical devices.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$20.0B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/FRE/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">FRE<span class="ml-2 text-sm text-slate-400">Firebrick Pharma Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.06</p><p class="text-xs font-semibold text-red-400">-29.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Firebrick Pharma Limited (ASX: FRE) is an Australian pharmaceutical company focused on developing novel antiviral therapies for common viral infections. Its lead product, Nasodine, is a broad-spectrum topical antiviral specifically targeting the common cold, currently undergoing Phase 3 clinical trials in the United States.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$16M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/GLH/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">GLH<span class="ml-2 text-sm text-slate-400">Global Health Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.07</p><p class="text-xs font-semibold text-red-400">-36.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Global Health Limited (GLH), listed on the ASX since April 4, 2000, is a healthcare technology company operating primarily in Australia. It specializes in developing and implementing digital health solutions, including telehealth platforms and electronic health record (EHR) systems for healthcare providers and patients across the country. Key products include its myhealthrecord and Telehealth platforms designed for Australian healthcare standards.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$5M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/GSS/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">GSS<span class="ml-2 text-sm text-slate-400">Genetic Signatures Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.14</p><p class="text-xs font-semibold text-red-400">-71.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Genetic Signatures Limited (ASX: GSS) is an Australian molecular diagnostics company specializing in rapid detection solutions for infectious diseases. Leveraging its proprietary 3Base™ technology, GSS develops and commercializes diagnostic kits for identifying pathogens in areas such as gastrointestinal, respiratory, and sexual health, primarily for pathology laboratories and hospitals globally.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$33M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/GTG/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">GTG<span class="ml-2 text-sm text-slate-400">Genetic Technologies Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.04</p><p class="text-xs font-semibold text-emerald-400">0.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Genetic Technologies Limited (ASX: GTG) is a biotechnology company focused on the development of genomics-based technologies for the prevention, diagnosis, and treatment of various diseases. Primarily operating in Australia, with potential global reach through partnerships, GTG has key products/services including diagnostic tools and therapies leveraging genetic insights. Specifically, it has developed the Ovarian Cancer Test and the Breast Cancer Test, utilizing DNA methylation biomarkers for early detection.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$-1</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/HIQ/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">HIQ<span class="ml-2 text-sm text-slate-400">Hitiq Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.02</p><p class="text-xs font-semibold text-red-400">-54.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Hitiq Limited (ASX: HIQ) is a health care equipment and services company listed on the Australian Stock Exchange since June 16, 2021. Primarily operating in Australia, HIQ focuses on developing and commercializing innovative medical devices for Diagnostic Imaging and Interventional Radiology, with a key product being its proprietary AI-driven Imaging Analysis Software. The company aims to enhance patient outcomes through advanced imaging solutions.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$9M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/HLS/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">HLS<span class="ml-2 text-sm text-slate-400">Healius Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.92</p><p class="text-xs font-semibold text-red-400">-34.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Healius Limited is one of Australia&#x27;s largest healthcare companies, providing extensive services in pathology, diagnostic imaging, and day hospitals. Operating a national network of collection centres, laboratories, and imaging sites, the company is a key player in the country&#x27;s diagnostic services landscape. Its core brands include Dorevitch Pathology, QML Pathology, Laverty Pathology, and Lumus Imaging.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$683M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/HMD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">HMD<span class="ml-2 text-sm text-slate-400">Heramed Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.04</p><p class="text-xs font-semibold text-emerald-400">110.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Heramed Limited (ASX: HMD) is an Australian-Israeli digital health company focused on remote pregnancy monitoring solutions. Its flagship product, HeraBEAT, is a medical-grade, CE-marked, and TGA-approved device enabling expectant mothers to monitor vital signs and fetal heart rate from home. The company operates globally by partnering with healthcare providers and health systems to integrate its technology into patient care pathways.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$49M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/HXL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">HXL<span class="ml-2 text-sm text-slate-400">Hexima Limited.</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-emerald-400">0.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Hexima Limited (HXL), listed on the ASX since 01/12/2020, focuses on the development of innovative biotechnological solutions within the health care sector, specifically targeting novel therapeutic approaches in the pharmaceuticals and life sciences space. Operating out of Australia, the company&#x27;s primary activities involve research and development of biologic products, though specific flagship products are currently under wraps due to its early listing stage. As a biotech firm, its operations are primarily R&amp;D-centric.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$-1</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IBX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IBX<span class="ml-2 text-sm text-slate-400">Imagion Biosystems Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.03</p><p class="text-xs font-semibold text-emerald-400">62.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Imagion Biosystems Limited is a clinical-stage biotechnology company developing non-radioactive imaging technology for early cancer detection. Its proprietary MagSense® platform uses magnetic nanoparticles to pinpoint cancer cells, with its lead program targeting HER2 breast cancer to improve staging accuracy and treatment decisions. The company operates primarily in Australia and the United States, focusing on advancing its technology through human clinical trials.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$12M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ICR/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ICR<span class="ml-2 text-sm text-slate-400">Intelicare Holdings Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.03</p><p class="text-xs font-semibold text-emerald-400">316.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Intelicare Holdings Limited (ASX: ICR) is an Australian technology company specializing in AI-powered assistive living solutions for the aged care and disability support sectors. Its flagship InteliCare platform uses sensors and artificial intelligence to monitor the well-being of individuals remotely, providing insights to carers and family members without invasive surveillance. The company primarily operates within the Australian market, aiming to improve independent living outcomes.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$16M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IDX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IDX<span class="ml-2 text-sm text-slate-400">Integral Diagnostics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->2.49</p><p class="text-xs font-semibold text-emerald-400">8.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Integral Diagnostics Limited (ASX: IDX) is a leading provider of diagnostic imaging services across Australia. The company operates an extensive network of radiology clinics offering a comprehensive range of services, including MRI, CT, ultrasound, X-ray, and nuclear medicine, to both public and private patients. IDX focuses on delivering high-quality patient care through advanced technology and highly skilled medical professionals in metropolitan and regional areas.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$936M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IDT/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IDT<span class="ml-2 text-sm text-slate-400">Idt Australia Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.05</p><p class="text-xs font-semibold text-red-400">-51.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Idt Australia Limited is an Australian pharmaceutical contract development and manufacturing organisation (CDMO) based in Boronia, Victoria. The company provides a full range of services from early-stage drug development and clinical trial material manufacturing to commercial scale production of finished drug products. IDT operates TGA and FDA-inspected facilities, specialising in high-containment active pharmaceutical ingredients (APIs) and sterile injectables.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$20M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ILA/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ILA<span class="ml-2 text-sm text-slate-400">Island Pharmaceuticals Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.41</p><p class="text-xs font-semibold text-emerald-400">151.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Island Pharmaceuticals Limited (ASX: ILA) is an early-stage Australian biotechnology company focused on the research, development, and commercialization of innovative therapeutic solutions in the pharmaceuticals and biotechnology sector. Primarily operating in Australia, with potential for global clinical trials, ILA is currently pre-revenue, concentrating on advancing its lead compound through clinical phases, targeting specific unmet medical needs. Key products/services include its proprietary drug candidate for [undisclosed target disease/condition, assuming specificity not publicly available, thus a placeholder].</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$113M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IIQ/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IIQ<span class="ml-2 text-sm text-slate-400">Inoviq Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.34</p><p class="text-xs font-semibold text-red-400">-17.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Inoviq Ltd is an Australian biotechnology company developing and commercializing next-generation diagnostics and exosome-based therapeutics for cancer. Its core technologies include the EXO-NET platform for exosome isolation and the SubB2M platform for developing blood tests for early cancer detection. The company&#x27;s lead programs are focused on developing non-invasive tests for ovarian and breast cancer.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$48M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IMC/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IMC<span class="ml-2 text-sm text-slate-400">Immuron Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.03</p><p class="text-xs font-semibold text-red-400">-52.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Immuron Limited (ASX: IMC) is an Australian biopharmaceutical company focused on the development and commercialisation of oral immunotherapies for the treatment of gut-mediated diseases. The company&#x27;s key assets include Travelan, an over-the-counter product for the prevention of traveler&#x27;s diarrhea, and IMM-124E, a lead prescription drug candidate currently in clinical development for liver diseases such as Non-Alcoholic Steatohepatitis (NASH) and Alcoholic Steatohepatitis (ASH). Immuron operates globally through distribution agreements for Travelan while advancing its drug pipeline.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$10M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IMM/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IMM<span class="ml-2 text-sm text-slate-400">Immutep Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.38</p><p class="text-xs font-semibold text-emerald-400">35.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Immutep Limited (ASX: IMM) is a biopharmaceutical company headquartered in Australia, specializing in immunotherapy for cancer and auto-immune diseases. It operates globally with research alliances and trials in the US and Europe. Key product is pep005, an immune-stimulating agent, and ipilimumab combination therapies. IMM has no commercial products yet, focusing on clinical trials.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$567M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IME/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IME<span class="ml-2 text-sm text-slate-400">Imexhs Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.47</p><p class="text-xs font-semibold text-emerald-400">17.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Imexhs Limited is a medical imaging software and services provider offering cloud-based Radiology Information Systems (RIS) and Picture Archiving and Communication Systems (PACS) via its HIRUKO platform. The company primarily operates in Latin America, serving hospitals and clinics with a recurring revenue, Software-as-a-Service (SaaS) model. It also provides remote teleradiology services where its radiologists interpret medical images for clients.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$25M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IMU/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IMU<span class="ml-2 text-sm text-slate-400">Imugene Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.26</p><p class="text-xs font-semibold text-red-400">-76.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Imugene Limited is an Australian clinical-stage immune-oncology company developing a range of novel cancer immunotherapies to activate the body’s immune system against cancer. Their pipeline focuses on oncolytic viruses (like VAXINIA) and B-cell immunotherapies (such as PD1-Vaxx and HER-Vaxx) for various solid tumors and blood cancers.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$85M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IMR/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IMR<span class="ml-2 text-sm text-slate-400">Imricor Medical Systems Inc.</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->1.92</p><p class="text-xs font-semibold text-emerald-400">39.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Imricor Medical Systems (IMR) is a medical device company pioneering real-time iCMR (interventional cardiac magnetic resonance) ablation procedures. The company designs, manufactures, and sells systems, including its flagship Advantage-MR EP Recorder and Vision-MR Ablation Catheter, which allow cardiologists to perform cardiac ablations inside an MRI scanner. This provides real-time 3D visualisation of the heart and ablations without the ionising radiation used in traditional x-ray guided procedures, with commercial operations currently focused in Europe.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$613M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IPD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IPD<span class="ml-2 text-sm text-slate-400">Impedimed Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.02</p><p class="text-xs font-semibold text-red-400">-53.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Impedimed Limited (ASX: IPD) is a medical technology company specializing in bioimpedance spectroscopy (BIS) technology. They develop and market devices, notably the SOZO digital health platform with L-Dex, for the early detection and management of lymphedema in cancer survivors and for general fluid status assessment. The company primarily operates globally, with a strong focus on market penetration in the United States healthcare sector.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$43M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IRX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IRX<span class="ml-2 text-sm text-slate-400">Inhalerx Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.02</p><p class="text-xs font-semibold text-red-400">-7.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Inhalerx Limited (ASX: IRX) is an Australian health technology company focused on the development and commercialisation of innovative drug delivery systems, primarily within the respiratory health sector. The company aims to improve therapeutic outcomes for patients with chronic respiratory conditions through novel inhaler technologies and enhanced medication delivery.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$5M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IVG/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IVG<span class="ml-2 text-sm text-slate-400">Invert Graphite Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.03</p><p class="text-xs font-semibold text-emerald-400">0.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Invert Graphite Limited (IVG) is an ASX-listed life sciences company focused on the development of graphene-based technologies for pharmaceutical applications, primarily operating in Australia with a growing presence in Asia-Pacific. Key products/services include graphene-enhanced drug delivery systems. The company leverages its proprietary technology to improve efficacy and reduce side effects of existing medications.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$13M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IVX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IVX<span class="ml-2 text-sm text-slate-400">Invion Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.08</p><p class="text-xs font-semibold text-red-400">-17.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Invion Limited (IVX) is an Australian biotechnology company dedicated to developing novel inhaled therapies for inflammatory and autoimmune diseases. Its primary focus is on advancing its lead drug candidate, IVX-Z001 (formerly INV102/Nadirad), which targets conditions such as idiopathic pulmonary fibrosis (IPF) and severe asthma. The company aims to address significant unmet medical needs through its therapeutic pipeline.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$7M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/IXC/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">IXC<span class="ml-2 text-sm text-slate-400">Invex Therapeutics Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.13</p><p class="text-xs font-semibold text-emerald-400">83.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Invex Therapeutics is a clinical-stage biopharmaceutical company focused on repurposing the drug Exenatide (under the brand name Presendin™) for neurological conditions associated with raised intracranial pressure. The company&#x27;s primary focus is its pivotal Phase III clinical trial, IIH Evolve, for the treatment of Idiopathic Intracranial Hypertension (IIH), a condition with a significant unmet medical need.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$9M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/LDX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">LDX<span class="ml-2 text-sm text-slate-400">Lumos Diagnostics Holdings Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.26</p><p class="text-xs font-semibold text-emerald-400">983.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Lumos Diagnostics Holdings Limited (ASX: LDX) is an Australian-based company developing and commercialising rapid, point-of-care (POC) diagnostic tests for infectious diseases. Their flagship product, FebriDx, aims to differentiate bacterial from viral infections within minutes, assisting clinicians in reducing unnecessary antibiotic prescriptions. Lumos operates globally with R&amp;D and manufacturing facilities in the US, targeting healthcare markets across North America, Europe, and Australia.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$214M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/LGP/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">LGP<span class="ml-2 text-sm text-slate-400">Little Green Pharma Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.13</p><p class="text-xs font-semibold text-emerald-400">0.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Little Green Pharma Ltd (ASX: LGP) is an Australian-based medicinal cannabis company focused on the cultivation, manufacturing, and global distribution of high-quality medicinal cannabis products. The company operates vertically integrated facilities and supplies a range of cannabis oils and dried flower products to patients in Australia and key international markets, primarily across Europe.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$37M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/LTP/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">LTP<span class="ml-2 text-sm text-slate-400">Ltr Pharma Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.51</p><p class="text-xs font-semibold text-emerald-400">10.9<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Ltr Pharma Limited (ASX: LTP) is a clinical-stage biotechnology company focused on developing innovative treatments for rare and underserved medical conditions. Operating primarily in Australia with research partnerships internationally, its key product is LTP-101, a novel oral therapeutic for Pulmonary Arterial Hypertension (PAH). The company leverages Australian research institutions for preclinical studies.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$92M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/M7T/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">M7T<span class="ml-2 text-sm text-slate-400">Mach7 Technologies Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.39</p><p class="text-xs font-semibold text-emerald-400">14.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Mach7 Technologies Limited (M7T) is an Australian company operating in the health care sector, providing medical imaging and informatics solutions to hospitals and healthcare providers globally, with a strong focus on interoperability and data integration. Key products include the Mach7 Dead Pixel, Mach7 ImageView, and Mach7 Data Integrity tools designed to enhance image management and workflow efficiency. Listed on the ASX since 2005, M7T serves clients across Australia, the United States, and internationally.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$94M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/MAP/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">MAP<span class="ml-2 text-sm text-slate-400">Microba Life Sciences Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.09</p><p class="text-xs font-semibold text-red-400">-57.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Microba Life Sciences Limited (ASX: MAP) is an Australian life sciences company focused on the human gut microbiome. They leverage their proprietary high-resolution microbiome analysis technology to develop both diagnostic services and novel therapeutic products. Their key offerings include the Microba Insight™ diagnostic test for gut health analysis and a pipeline of microbiome-based therapeutic candidates targeting various chronic diseases.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$53M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/MEM/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">MEM<span class="ml-2 text-sm text-slate-400">Memphasys Limited.</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-22.2<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Memphasys Limited (ASX: MEM) is a biotechnology company focusing on developing innovative medical devices, notably the MemProsys platform, aimed at improving sperm selection for assisted reproductive technologies. Primarily operating in Australia, with potential for global market expansion, key products/services include proprietary microfluidic devices for fertility treatments. Based in Melbourne, Australia, with research and development efforts concentrated domestically.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$19M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/MSB/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">MSB<span class="ml-2 text-sm text-slate-400">Mesoblast Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->2.39</p><p class="text-xs font-semibold text-emerald-400">21.9<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Mesoblast Limited (ASX: MSB) is an Australian-based biotechnology company focused on developing allogeneic mesenchymal stromal cell (MSC) therapies for inflammatory diseases. Their lead product candidate, remestemcel-L (Ryoncil), is in development for acute graft versus host disease (aGVHD) and has been submitted for FDA approval. The company also has other pipeline candidates, including rexlemestrocel-L, targeting chronic heart failure and chronic lower back pain, operating globally from its Australian base.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$3.2B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/MVF/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">MVF<span class="ml-2 text-sm text-slate-400">Monash Ivf Group Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.69</p><p class="text-xs font-semibold text-red-400">-38.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Monash IVF Group Limited operates fertility clinics across Australia and New Zealand, providing assisted reproductive technology (ART) services including IVF, IUI, and fertility testing. They also offer complementary gynecological and obstetric services. With a network of clinics, the company serves patients through direct services and partnerships with medical professionals.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$275M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/MVP/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">MVP<span class="ml-2 text-sm text-slate-400">Medical Developments International Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.46</p><p class="text-xs font-semibold text-red-400">-17.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Medical Developments International Limited (MVP) is an Australian pharmaceutical company specializing in the development and commercialisation of pain management and respiratory products. Its flagship product is Penthrox (the &#x27;green whistle&#x27;), an inhaled fast-acting analgesic for acute pain, distributed across Australia, Europe, and other international markets. The company focuses on expanding its global footprint for Penthrox and developing new product applications.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$55M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/MX1/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">MX1<span class="ml-2 text-sm text-slate-400">Micro-X Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.09</p><p class="text-xs font-semibold text-emerald-400">45.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Micro-X Limited is an Adelaide-based high-tech company that designs and manufactures ultra-lightweight, mobile X-ray imaging systems. Its core innovation is a proprietary Carbon Nanotube (CNT) X-ray emitter, which enables smaller and lighter devices than traditional systems. The company&#x27;s flagship product is the &#x27;Rover&#x27; mobile X-ray for hospitals, and it is developing new applications for its technology in airport security and pre-hospital stroke diagnosis.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$65M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/MYX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">MYX<span class="ml-2 text-sm text-slate-400">Mayne Pharma Group Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->2.70</p><p class="text-xs font-semibold text-red-400">-62.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Mayne Pharma Group Limited (ASX: MYX) is an Australian-based specialty pharmaceutical company that develops, manufactures, and commercialises a portfolio of branded and generic pharmaceutical products. Operating primarily in Australia and the United States, the company focuses on therapeutic areas such as women&#x27;s health and dermatology, leveraging its drug delivery technologies.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$222M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/NC6/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">NC6<span class="ml-2 text-sm text-slate-400">Nanollose Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.07</p><p class="text-xs font-semibold text-emerald-400">80.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Nanollose Limited (ASX: NC6) is an Australia-based biotechnology company focused on developing novel, sustainable biomaterials. The company operates primarily in Australia and is known for its innovative approach to producing cellulose from organic waste, targeting applications in health care, textiles, and more. Key products include its patented nanocellulose materials for wound care and cosmetic applications.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$23M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/NAN/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">NAN<span class="ml-2 text-sm text-slate-400">Nanosonics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->3.91</p><p class="text-xs font-semibold text-red-400">-14.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Nanosonics is a global infection prevention company that develops and commercialises innovative technologies to reduce the risk of cross-contamination in medical settings. Its flagship product, the Trophon2, is an automated system providing high-level disinfection (HLD) for ultrasound probes. The company operates on a &#x27;razor-and-blade&#x27; model, selling capital equipment and generating recurring revenue from the sale of associated high-margin consumables.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$1.2B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/NEU/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">NEU<span class="ml-2 text-sm text-slate-400">Neuren Pharmaceuticals Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->13.20</p><p class="text-xs font-semibold text-emerald-400">10.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Neuren Pharmaceuticals is an Australian biotechnology company developing therapies for rare and debilitating neurological disorders. Its first drug, trofinetide (marketed as DAYBUE™), is approved and sold in the United States for the treatment of Rett syndrome, generating significant royalty revenue. The company is advancing its pipeline candidate, NNZ-2591, through clinical trials for other serious conditions including Phelan-McDermid, Angelman, and Pitt Hopkins syndromes.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$1.9B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/NOX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">NOX<span class="ml-2 text-sm text-slate-400">Noxopharm Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.07</p><p class="text-xs font-semibold text-red-400">-17.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Noxopharm Limited is a clinical-stage Australian biotechnology company focused on developing novel treatments for cancer. Its core focus is on its proprietary idronoxil (Veyonda®) technology platform, which aims to enhance the effectiveness of standard cancer therapies like chemotherapy and radiotherapy. The company&#x27;s operations are centered on progressing its drug candidates through preclinical and clinical trials to address unmet needs in oncology.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$19M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/NSB/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">NSB<span class="ml-2 text-sm text-slate-400">Neuroscientific Biopharmaceuticals Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.14</p><p class="text-xs font-semibold text-emerald-400">278.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Neuroscientific Biopharmaceuticals Ltd (NSB) is an Australian clinical-stage pharmaceutical company focused on developing novel peptide-based drugs for neurological and neurodegenerative disorders. Their lead drug candidate, EmtinB, targets conditions such as Alzheimer&#x27;s disease, Multiple Sclerosis, and glaucoma, aiming to address significant unmet medical needs. The company is advancing its proprietary therapeutic compounds through various stages of preclinical and clinical development.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$47M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/NTI/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">NTI<span class="ml-2 text-sm text-slate-400">Neurotech International Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-54.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Neurotech International Limited (ASX: NTI) is a clinical-stage biotechnology company focused on developing and commercialising neuro-protective and neuro-modulatory pharmaceuticals. Its lead investigational drug, NTI164, is an orally administered full-spectrum cannabinoid product currently undergoing clinical trials for neurological disorders such as Autism Spectrum Disorder (ASD), Rett Syndrome, and Multiple Sclerosis.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$18M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/NUZ/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">NUZ<span class="ml-2 text-sm text-slate-400">Neurizon Therapeutics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.10</p><p class="text-xs font-semibold text-red-400">-23.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Neurizon Therapeutics is a clinical-stage Australian biotechnology company focused on developing novel treatments for neurodegenerative diseases. Its lead candidate, NZ-101, is a first-in-class small molecule inhibitor targeting neuroinflammation and is currently in Phase 2 clinical trials for the treatment of relapsing-remitting Multiple Sclerosis (MS). The company operates primarily from research facilities in Melbourne, Australia.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$65M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/NXS/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">NXS<span class="ml-2 text-sm text-slate-400">Next Science Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.14</p><p class="text-xs font-semibold text-emerald-400">31.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Next Science Limited (ASX: NXS) is an Australian medical technology company focused on the development and commercialization of patented XBIO™ technology, designed to disrupt bacterial biofilms and reduce the impact of infection. The company offers a range of products for surgical site infection prevention, chronic wound management, and medical device infection control, operating primarily in the United States and expanding globally.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$-1</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/NXN/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">NXN<span class="ml-2 text-sm text-slate-400">Nexsen Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.17</p><p class="text-xs font-semibold text-emerald-400">0.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Nexsen Limited is a clinical-stage Australian biotechnology company focused on developing novel cell therapies for hard-to-treat solid tumours. Headquartered in Melbourne, its lead candidate, NXN-101, is an autologous CAR-T therapy targeting a novel antigen prevalent in pancreatic and colorectal cancers. The company is currently advancing NXN-101 through a Phase 1a clinical trial to establish safety and tolerability.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$39M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/NYR/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">NYR<span class="ml-2 text-sm text-slate-400">Nyrada Inc.</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.82</p><p class="text-xs font-semibold text-emerald-400">662.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Nyrada Inc. is an Australian-based biotechnology company focused on the development of novel neuroprotectants and cardiovascular therapeutics. The company&#x27;s lead programs target significant medical needs such as traumatic brain injury, stroke, and certain cardiovascular diseases, with drug candidates in pre-clinical and early clinical development phases. Nyrada operates primarily in the research and development sector, aiming to develop first-in-class treatments.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$225M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/OCA/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">OCA<span class="ml-2 text-sm text-slate-400">Oceania Healthcare Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.68</p><p class="text-xs font-semibold text-emerald-400">24.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Oceania Healthcare Limited (ASX: OCA) operates healthcare facilities, focusing on aged care and retirement living in New Zealand. With operations primarily in NZ, key services include residential care, retirement villages, and healthcare support. Listed on the ASX since 05/05/2017.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$525M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/OCC/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">OCC<span class="ml-2 text-sm text-slate-400">Orthocell Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.95</p><p class="text-xs font-semibold text-red-400">-36.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Orthocell Limited is an Australian regenerative medicine company focused on developing and commercialising products for the repair of soft tissue injuries. The company&#x27;s key products include Remplir™ (formerly CelGro®), a collagen medical device for nerve and tendon repair, and Ortho-ATI®, a first-in-class cell therapy for treating chronic tendon injuries. Orthocell is transitioning from R&amp;D to commercialisation, with products approved for sale in Australia, Europe, and the United States.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$250M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/OIL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">OIL<span class="ml-2 text-sm text-slate-400">Optiscan Imaging Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.09</p><p class="text-xs font-semibold text-red-400">-35.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Optiscan Imaging Limited is a Melbourne-based medical technology company pioneering the development of confocal endomicroscopy imaging systems for real-time, in-vivo cellular imaging. Their flagship product, the InVivage® system, acts as a &#x27;digital biopsy&#x27; tool, enabling surgeons and clinicians to view tissue at a microscopic level during procedures, primarily for cancer detection and surgical margin assessment. The company is advancing its technology for various applications, including oral cancer, breast cancer, and neurosurgery.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$94M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ONE/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ONE<span class="ml-2 text-sm text-slate-400">Oneview Healthcare Plc</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.29</p><p class="text-xs font-semibold text-red-400">-3.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Oneview Healthcare provides a cloud-based Care Experience Platform (CXP) for hospitals and healthcare systems, designed to improve the patient experience and streamline clinical workflows. The platform integrates with existing hospital IT infrastructure to deliver personalised education, entertainment, communication tools, and meal ordering directly to the patient&#x27;s bedside device. Operating globally with key markets in the US, Australia, and the Middle East, Oneview aims to empower patients and support care teams through its digital solution.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$230M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/OPT/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">OPT<span class="ml-2 text-sm text-slate-400">Opthea Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.60</p><p class="text-xs font-semibold text-emerald-400">0.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal eye diseases. Its lead product candidate, sozinibercept (OPT-302), is in Phase 3 clinical trials for the treatment of wet age-related macular degeneration (wet AMD) and Diabetic Macular Edema (DME). The company&#x27;s strategy is to develop sozinibercept as a combination therapy with standard-of-care anti-VEGF-A drugs to achieve superior vision outcomes for patients.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$-1</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/OSX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">OSX<span class="ml-2 text-sm text-slate-400">Osteopore Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-55.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Osteopore Limited (ASX: OSX) is a medtech company developing proprietary 3D printed scaffolds for tissue regeneration, focusing on bone repair. Operating in Australia with products under development for global markets, its key product is a bioresorbable scaffold for orthopedic and craniofacial applications. Based in Perth, Western Australia, it leverages local research partnerships.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$5M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/OSL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">OSL<span class="ml-2 text-sm text-slate-400">Oncosil Medical Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.72</p><p class="text-xs font-semibold text-red-400">-60.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Oncosil Medical Ltd is a medical device company focused on developing and commercialising localised radiation therapies for cancer. Its lead product, the OncoSil™ device, is a targeted brachytherapy treatment for patients with locally advanced, unresectable pancreatic cancer. The company is primarily focused on driving commercial adoption in Europe, where it has CE Mark approval, and pursuing regulatory approval in the United States.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$13M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PAB/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PAB<span class="ml-2 text-sm text-slate-400">Patrys Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.04</p><p class="text-xs font-semibold text-emerald-400">16.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Patrys Limited (ASX: PAB) is an Australian clinical-stage biotechnology company focused on developing novel antibody-based therapeutics for cancer. Their lead product candidate, PAT-DX1, is a humanised IgG antibody designed to penetrate the blood-brain barrier and target DNA damage repair pathways in cancer cells, aiming to treat both primary and metastatic brain cancers, as well as other solid tumours.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$20M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PAR/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PAR<span class="ml-2 text-sm text-slate-400">Paradigm Biopharmaceuticals Limited..</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.30</p><p class="text-xs font-semibold text-red-400">-7.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Paradigm Biopharmaceuticals is a late-stage drug development company focused on repurposing the drug pentosan polysulfate sodium (branded as Zilosul®) for treating unmet needs in musculoskeletal disorders. The company&#x27;s lead program is a pivotal Phase 3 clinical trial investigating Zilosul® as a potential disease-modifying treatment for knee osteoarthritis (OA). Paradigm operates primarily in Australia and the United States, targeting major global pharmaceutical markets.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$130M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PCK/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PCK<span class="ml-2 text-sm text-slate-400">Painchek Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.23</p><p class="text-xs font-semibold text-red-400">-11.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Painchek Ltd (ASX: PCK) is an Australian health technology company that has developed and commercialised the Painchek® app, an AI-powered pain assessment tool. This medical device uses facial recognition and AI to assess and document pain in individuals who cannot reliably verbalise it, primarily targeting people with dementia in aged care and non-verbal children. The company operates in Australia, the UK, New Zealand, and Canada, aiming to address a significant unmet clinical need globally.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$54M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PEB/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PEB<span class="ml-2 text-sm text-slate-400">Pacific Edge Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.17</p><p class="text-xs font-semibold text-emerald-400">50.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Pacific Edge Limited (ASX: PEB) is a New Zealand-based healthcare company specialising in the development and commercialisation of non-invasive diagnostic tests for the early detection and management of cancer. Its flagship product suite, Cxbladder, focuses on bladder cancer detection and surveillance, primarily targeting the significant US market alongside New Zealand and other international regions.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$169M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PER/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PER<span class="ml-2 text-sm text-slate-400">Percheron Therapeutics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-27.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Percheron Therapeutics Limited (ASX: PER) is an Australian clinical-stage biotechnology company focused on developing novel psychedelic medicines for the treatment of various mental health conditions. Its lead program, PER-003, is being advanced for indications such as Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD), aiming to address significant unmet medical needs.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$9M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PGC/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PGC<span class="ml-2 text-sm text-slate-400">Paragon Care Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.20</p><p class="text-xs font-semibold text-red-400">-45.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Paragon Care Limited is a leading provider of medical equipment, devices, and consumables to the health and aged care sectors across Australia and New Zealand. The company operates through several pillars, including diagnostics, medical devices, capital equipment, and services. PGC acts as a key distributor for global manufacturers, offering a diversified portfolio of products to hospitals, medical clinics, and aged care facilities.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$348M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PIQ/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PIQ<span class="ml-2 text-sm text-slate-400">Proteomics International Laboratories Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.46</p><p class="text-xs font-semibold text-red-400">-8.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Proteomics International Laboratories Ltd (ASX: PIQ) is a medical technology company focused on proteomics, the large-scale study of proteins. Its lead product, PromarkerD, is a predictive diagnostic test for diabetic kidney disease, which it is commercialising globally. The company operates from its headquarters in Perth, Western Australia, and is also developing a pipeline of other diagnostic tests for diseases like endometriosis and oesophageal cancer.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$81M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PKP/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PKP<span class="ml-2 text-sm text-slate-400">Peak Processing Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.02</p><p class="text-xs font-semibold text-red-400">-10.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Peak Processing Limited (ASX: PKP) is a specialist contract development and manufacturing organisation (CDMO) operating within Australia&#x27;s life sciences sector. The company provides formulation, processing, and packaging services for therapeutic goods from its TGA-licensed facility. PKP focuses on high-growth niches, particularly medicinal cannabis oils, tinctures, and other novel drug delivery systems for third-party pharmaceutical and biotech clients.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$17M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PME/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PME<span class="ml-2 text-sm text-slate-400">Pro Medicus Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->164.93</p><p class="text-xs font-semibold text-red-400">-17.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Pro Medicus Limited (PME) is an Australian health care technology company focused on diagnostic imaging solutions. Headquartered in Melbourne, it operates predominantly in Australia and internationally, offering products like Xercise, MedMovie, and iMIX, which cater to medical imaging, patient engagement, and imaging data management. Key services include imaging software and related support.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$17.4B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PTX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PTX<span class="ml-2 text-sm text-slate-400">Prescient Therapeutics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.07</p><p class="text-xs font-semibold text-emerald-400">51.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer therapies. Based in Australia, it focuses on its next-generation CAR-T platform, OmniCAR, designed to enhance control and safety, alongside a pipeline of targeted therapies including PTX-100 for T-cell lymphomas.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$78M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PYC/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PYC<span class="ml-2 text-sm text-slate-400">Pyc Therapeutics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->1.50</p><p class="text-xs font-semibold text-emerald-400">22.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Pyc Therapeutics Limited (ASX: PYC) is an Australian clinical-stage biotechnology company focused on developing a new generation of RNA therapeutics to treat blinding eye diseases and neurodevelopmental disorders. Leveraging its proprietary drug delivery platform, PYC aims to deliver RNA drugs into cells to address previously untreatable genetic conditions, operating primarily out of Australia with global ambitions for its pipeline.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$881M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/RAC/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">RAC<span class="ml-2 text-sm text-slate-400">Racura Oncology Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->2.30</p><p class="text-xs font-semibold text-emerald-400">116.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Ratura Oncology Ltd (ASX: RAC) is an Australian-listed biotechnology company focused on the discovery, development, and commercialization of novel therapeutic candidates for the treatment of various cancers. Operating primarily in the preclinical and clinical trial phases, the company aims to address unmet medical needs within oncology by advancing its pipeline of drug candidates.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$416M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/RAD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">RAD<span class="ml-2 text-sm text-slate-400">Radiopharm Theranostics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.02</p><p class="text-xs font-semibold text-red-400">-18.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Radiopharm Theranostics Limited (ASX: RAD), listed in November 2021, operates in the Health Care sector focusing on Pharmaceuticals, Biotechnology, and Life Sciences. They are developing targeted theranostic products for cancer treatment, primarily working in Australia with potential for global market expansion. Key products/services include radiopharmaceuticals for both diagnostic imaging and targeted cancer therapy.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$78M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/RCE/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">RCE<span class="ml-2 text-sm text-slate-400">Recce Pharmaceuticals Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.59</p><p class="text-xs font-semibold text-emerald-400">63.9<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Recce Pharmaceuticals is a clinical-stage biotechnology company developing a new class of synthetic anti-infectives to address the global health problem of antibiotic-resistant superbugs. Headquartered in Australia, its lead product, RECCE® 327, is a broad-spectrum antibiotic being evaluated in clinical trials for serious and life-threatening infections including sepsis and diabetic foot ulcers.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$166M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/REG/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">REG<span class="ml-2 text-sm text-slate-400">Regis Healthcare Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->6.66</p><p class="text-xs font-semibold text-red-400">-1.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Regis Healthcare Limited (ASX: REG) is one of Australia&#x27;s largest providers of residential aged care services. The company operates numerous aged care facilities across Australia, offering a comprehensive range of services including permanent accommodation, dementia care, respite care, and palliative care for the elderly. Regis focuses on delivering high-quality care within a regulated framework.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$2.0B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/RHC/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">RHC<span class="ml-2 text-sm text-slate-400">Ramsay Health Care Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->36.02</p><p class="text-xs font-semibold text-emerald-400">5.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Ramsay Health Care Limited is a leading global operator of private hospitals and healthcare facilities. It provides a comprehensive range of medical, surgical, rehabilitation, and mental health services across Australia, Europe (France, UK, Nordics), and Asia. The company focuses on delivering high-quality patient care within its extensive network of hospitals and day surgeries.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$8.2B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/RGT/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">RGT<span class="ml-2 text-sm text-slate-400">Argent Biopharma Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.05</p><p class="text-xs font-semibold text-red-400">-68.2<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Argent Biopharma is an Australian clinical-stage biotechnology company focused on developing novel therapies for inflammatory and autoimmune diseases. Its lead drug candidate, ARG-007, is an intravenous therapeutic being developed to treat Chronic Obstructive Pulmonary Disease (COPD) and other significant unmet medical needs. The company is advancing ARG-007 through the pre-clinical and clinical trial process to establish its safety and efficacy.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$5M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/RHY/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">RHY<span class="ml-2 text-sm text-slate-400">Rhythm Biosciences Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.23</p><p class="text-xs font-semibold text-emerald-400">193.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Rhythm Biosciences Limited (ASX: RHY) is an Australian medical diagnostics company focused on developing and commercialising its lead product, ColoSTAT, a simple blood test for the early detection of colorectal cancer. The company aims to provide a more accessible and non-invasive screening solution globally, primarily targeting markets in Australia, Europe, and the USA.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$57M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/RHT/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">RHT<span class="ml-2 text-sm text-slate-400">Resonance Health Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.05</p><p class="text-xs font-semibold text-emerald-400">23.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Resonance Health is a medical technology company specializing in the development and delivery of non-invasive medical imaging analysis services. Operating globally, the company&#x27;s core products include FerriScan® for liver iron concentration measurement and HepaFat-Scan® for liver fat quantification, both utilising MRI data. RHT is increasingly focused on leveraging artificial intelligence (AI) to expand its suite of diagnostic tools for various diseases.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$22M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/RMD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">RMD<span class="ml-2 text-sm text-slate-400">Resmed Inc</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->37.46</p><p class="text-xs font-semibold text-emerald-400">7.2<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">ResMed Inc (RMD) is a global leader in respiratory therapies and sleep apnea solutions, operating worldwide with a strong presence in Australia. Key products include CPAP (Continuous Positive Airway Pressure) machines like AirSense and AirFit masks. The company is headquartered in San Diego, USA, but listed on the ASX.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$52.0B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/RNV/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">RNV<span class="ml-2 text-sm text-slate-400">Renerve Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.12</p><p class="text-xs font-semibold text-red-400">-7.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Renerve Limited (ASX: RNV) is a Australian health care company operating in the equipment and services sector. Specifically, Renerve focuses on developing innovative neuromodulation solutions for chronic pain management, primarily targeting the Australian market with plans for Southeast Asian expansion. Its key product, the NeuroPace System, offers a minimally invasive, implantable device for precise nerve stimulation.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$20M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/RYM/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">RYM<span class="ml-2 text-sm text-slate-400">Ryman Healthcare Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->2.35</p><p class="text-xs font-semibold text-red-400">-8.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Ryman Healthcare Limited is a leading New Zealand-based developer and operator of integrated retirement villages, providing independent living, serviced apartments, and comprehensive aged care facilities. The company operates primarily across New Zealand and in Victoria, Australia, catering to the growing demand for quality senior living and care services.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$2.4B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/SDI/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">SDI<span class="ml-2 text-sm text-slate-400">Sdi Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.95</p><p class="text-xs font-semibold text-emerald-400">9.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Sdi Limited is an Australian-based developer, manufacturer, and marketer of specialist dental materials for the global professional dental industry. Headquartered in Victoria, the company exports its products to over 100 countries. Its core product lines include restorative materials (composites, amalgams), adhesives, and aesthetic products, most notably the &#x27;Pola&#x27; brand of tooth whitening systems.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$114M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/SHG/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">SHG<span class="ml-2 text-sm text-slate-400">Singular Health Group Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.23</p><p class="text-xs font-semibold text-red-400">-4.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Singular Health Group Ltd develops cutting-edge 3D medical visualisation technology, primarily through its Volumetric Rendering Platform (VRP). This platform converts traditional 2D medical scans into interactive 3D anatomical models, designed to improve surgical planning, patient education, and implant design within the health care sector globally, with a focus on markets like Australia and the USA.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$74M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/SHL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">SHL<span class="ml-2 text-sm text-slate-400">Sonic Healthcare Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->22.57</p><p class="text-xs font-semibold text-red-400">-12.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Sonic Healthcare is a leading global medical diagnostics company, providing laboratory medicine, pathology, and radiology services. It operates in over eight countries, including Australia, the USA, and Germany, serving clinicians, hospitals, and medical centres with a comprehensive range of diagnostic testing and imaging.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$11.2B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/SIG/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">SIG<span class="ml-2 text-sm text-slate-400">Sigma Healthcare Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->3.16</p><p class="text-xs font-semibold text-emerald-400">9.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Sigma Healthcare Limited is a leading Australian healthcare company, primarily focused on the wholesale distribution of pharmaceutical goods and medical consumables. It supports a large network of community pharmacies across Australia under brands such as Amcal, Guardian, and Discount Drug Stores. The company is currently undergoing a transformative proposed merger with Chemist Warehouse Group, aiming to create a vertically integrated pharmacy and distribution powerhouse.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$36.5B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/SLD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">SLD<span class="ml-2 text-sm text-slate-400">Saluda Medical, Inc.</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->1.21</p><p class="text-xs font-semibold text-red-400">-2.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Saluda Medical, Inc. (ASX: SLD) operates in the Health Care Equipment &amp; Services sector, specifically developing and commercializing next-generation spinal cord stimulation (SCS) technologies in Australia and internationally. Key products include the Saluda Pulse Generators with proprietary software for personalized pain management. The company is headquartered in Australia with primary operations in the APAC region.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$315M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/SNZ/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">SNZ<span class="ml-2 text-sm text-slate-400">Summerset Group Holdings Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->9.70</p><p class="text-xs font-semibold text-red-400">-4.2<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Summerset Group Holdings Limited operates retirement villages and aged care facilities, primarily across New Zealand and Australia. Its services include independent living, assisted living, and dementia care. SNZ focuses on senior housing solutions with a portfolio of over 5,000 homes.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$2.4B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/SNT/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">SNT<span class="ml-2 text-sm text-slate-400">Syntara Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.03</p><p class="text-xs font-semibold text-red-400">-55.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Syntara Limited is a clinical-stage Australian biotechnology company developing drugs for diseases involving fibrosis and inflammation. Its lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently in a Phase 2 clinical trial for the bone marrow cancer myelofibrosis. The company is also exploring its drug candidates for other indications, including liver and pancreatic cancer.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$56M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/SOM/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">SOM<span class="ml-2 text-sm text-slate-400">Somnomed Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.64</p><p class="text-xs font-semibold text-emerald-400">14.9<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Somnomed Limited (ASX: SOM) is a healthcare equipment company focused on oral appliance therapy for the treatment of sleep disorders, primarily obstructive sleep apnea (OSA). Operating predominantly in Australia and with international presence, its key products include the mandibular advancement devices (MADs) like the SomnoMed ACTIVATETM and the SomnoMed AIRVTM. These devices are custom-made for each patient to advance the jaw, keeping the airway open during sleep.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$143M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/SPL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">SPL<span class="ml-2 text-sm text-slate-400">Starpharma Holdings Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.40</p><p class="text-xs font-semibold text-emerald-400">325.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Starpharma Holdings Limited (SPL) is an Australian biotech company specializing in pharmaceuticals and life sciences. Headquartered in Melbourne, SPL operates globally, focusing on drug delivery technologies, with its lead product being Dendrimers, particularly the proprietary DuraGel technology for enhancing drug efficacy and safety. Key products include clinical-stage oncology and infectious disease treatments.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$172M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/TD1/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">TD1<span class="ml-2 text-sm text-slate-400">Tali Digital Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.05</p><p class="text-xs font-semibold text-red-400">-48.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Tali Digital Limited develops and commercialises digital therapeutics aimed at assessing and improving cognitive function, specifically attention, in early childhood. The company&#x27;s key products are TALI Detect, a game-based assessment tool, and TALI Train, a digital attention training program, both targeting neurodevelopmental conditions like ADHD and autism. TD1 primarily operates in the Australian market but seeks global partnerships for expansion.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$2M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/TLX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">TLX<span class="ml-2 text-sm text-slate-400">Telix Pharmaceuticals Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->10.13</p><p class="text-xs font-semibold text-red-400">-61.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Telix Pharmaceuticals is an Australian-based, global biopharmaceutical company focused on developing and commercialising radiopharmaceuticals for cancer diagnosis and treatment. Its lead commercial product, Illuccix, is a prostate cancer imaging agent generating significant revenue primarily in the United States and Europe. The company is advancing a deep pipeline of &#x27;theranostic&#x27; candidates designed to both image and treat cancers, with a key focus on prostate and kidney cancer.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$3.4B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/TRJ/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">TRJ<span class="ml-2 text-sm text-slate-400">Trajan Group Holdings Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.67</p><p class="text-xs font-semibold text-red-400">-21.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Trajan Group Holdings Limited (ASX: TRJ) is a global developer and manufacturer of analytical and life science products and solutions, with a focus on precision measurement devices and workflows. The company provides specialized components, automation tools, and integrated solutions primarily for the global analytical and healthcare sectors, including chromatography consumables and liquid handling systems. Operating internationally, Trajan aims to enhance the accuracy and efficiency of scientific analysis and personalized healthcare.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$102M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/TRI/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">TRI<span class="ml-2 text-sm text-slate-400">Trivarx Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.02</p><p class="text-xs font-semibold text-emerald-400">40.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Trivarx Ltd is an Australian medical technology company developing its proprietary &#x27;Cardi-Dx&#x27; point-of-care diagnostic platform. The device is designed for the rapid detection of key cardiac biomarkers from a single drop of blood, targeting the early and accurate diagnosis of acute cardiac events in emergency departments and clinics. The company is currently advancing the Cardi-Dx system through clinical trials and regulatory approval pathways in Australia and Europe.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$22M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/TRU/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">TRU<span class="ml-2 text-sm text-slate-400">Truscreen Group Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-44.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Truscreen Group Limited (ASX: TRU) develops, manufactures, and sells the TruScreen device, an optical and digital cerviscope for real-time, non-invasive cervical cancer screening. The technology aims to provide immediate, accurate results at the point of care, addressing limitations of traditional Pap smears and HPV tests. Truscreen primarily operates in key markets such as China, Vietnam, Mexico, and other developing nations.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$11M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/TRP/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">TRP<span class="ml-2 text-sm text-slate-400">Tissue Repair Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.20</p><p class="text-xs font-semibold text-red-400">-22.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Tissue Repair Ltd is an Australian clinical-stage biopharmaceutical company focused on developing advanced wound healing solutions. The company&#x27;s core technology is a unique glucan polymer, with its lead product, Glucoprime (TR-987), being a topical gel designed to treat chronic wounds and post-surgical scarring. TRP&#x27;s strategy is to progress its assets through clinical trials to demonstrate safety and efficacy before seeking commercialisation partnerships.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$12M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/TTX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">TTX<span class="ml-2 text-sm text-slate-400">Tetratherix Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->3.80</p><p class="text-xs font-semibold text-red-400">-24.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Tetratherix Limited (ASX: TTX) is an Australian biotechnology company focused on the discovery and development of novel therapeutic candidates for underserved medical conditions, with a primary focus on oncology, immunology, or rare diseases. Operating from its research facilities in Australia, the company leverages advanced drug discovery platforms to progress its proprietary pipeline from pre-clinical stages towards human clinical trials.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$205M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/UBI/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">UBI<span class="ml-2 text-sm text-slate-400">Universal Biosensors Inc.</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-79.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Universal Biosensors Inc. (ASX: UBI) develops point-of-care diagnostic and monitoring systems for biosensors. Primarily operating in Australia and targeting global healthcare markets, its key products are based on its proprietary biosensor technology for glucose and other biomarker detections. UBI partners with international pharmaceutical companies for co-development and commercialization.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$-1</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/UCM/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">UCM<span class="ml-2 text-sm text-slate-400">Uscom Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-60.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Uscom Limited (UCM) is an Australian medical device company that develops, manufactures, and markets non-invasive cardiovascular and pulmonary diagnostic equipment. Its key products include the USCOM 1A for advanced cardiac output monitoring, Uscom BP+ for central blood pressure, and SpiroSonic digital ultrasonic spirometers for respiratory diagnostics, distributed globally to hospitals and clinics.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$-1</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/VBS/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">VBS<span class="ml-2 text-sm text-slate-400">Vectus Biosystems Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.14</p><p class="text-xs font-semibold text-emerald-400">77.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Vectus Biosystems Limited (ASX: VBS) is an Australian biotechnology company dedicated to the discovery and development of novel small molecule drugs for fibrotic diseases. Their primary focus is on conditions like heart failure and kidney fibrosis, leveraging their expertise in the Renin-Angiotensin-Aldosterone System (RAAS) to progress proprietary drug candidates through pre-clinical and early clinical stages within Australia.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$6M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/VFX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">VFX<span class="ml-2 text-sm text-slate-400">Visionflex Group Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.09</p><p class="text-xs font-semibold text-red-400">-37.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Visionflex Group Limited (ASX: VFX) is an Australian medical technology company developing and commercialising innovative telehealth solutions. Their core offering includes the Visionflex telehealth platform and the ProEX Series of integrated medical devices, enabling remote diagnostic examinations and consultations. The company aims to facilitate high-quality healthcare delivery across diverse settings, from hospitals and aged care facilities to remote communities and defence operations.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$8M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/VFY/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">VFY<span class="ml-2 text-sm text-slate-400">Vitrafy Life Sciences Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->1.65</p><p class="text-xs font-semibold text-emerald-400">37.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Vitrafy Life Sciences Limited (ASX: VFY), listed since November 26, 2024, is an Australian biotechnology company focused on developing innovative therapeutics for underserved diseases. Operating primarily in Australia with potential for global product reach, their key product/service involves researching and developing novel biologic treatments, currently in pre-clinical stages. Specific focus areas include oncology and rare genetic disorders.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$103M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/VHL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">VHL<span class="ml-2 text-sm text-slate-400">Vitasora Health Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.02</p><p class="text-xs font-semibold text-red-400">-48.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Vitasora Health Limited (VHL) is an Australian healthcare company focused on developing innovative medical devices and diagnostics within the Health Care Equipment &amp; Services sector. Operating primarily in Australia, with potential regional expansion plans, VHL&#x27;s key products include specialized diagnostic tools for cardiology and respiratory diseases. As of its last update, the company has been listed on the ASX since 2000, indicating a long-standing presence in the market.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$41M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/VIT/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">VIT<span class="ml-2 text-sm text-slate-400">Vitura Health Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.06</p><p class="text-xs font-semibold text-red-400">-28.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Vitura Health Limited (ASX: VIT) operates in Australia, specializing in sleep disorder diagnostics and treatments. Specifically, they focus on respiratory and sleep care services, offering solutions like sleep diagnostics and therapy management across their clinics. With a presence in key Australian urban centers, their primary services include at-home sleep testing and personalized treatment plans.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$38M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/VLS/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">VLS<span class="ml-2 text-sm text-slate-400">Vita Life Sciences Limited..</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->2.70</p><p class="text-xs font-semibold text-emerald-400">42.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Vita Life Sciences Limited (VLS) is an Australian-based company specializing in the manufacture, distribution, and marketing of a diverse range of vitamins, minerals, and dietary supplements. Operating primarily across Australia and Southeast Asia, the company focuses on health and wellness products under well-known brands such as VitaHealth, VitaScience, and Herbs of Gold. Their portfolio includes therapeutic supplements designed to support general health, immune function, and specific health concerns.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$155M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ZLD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ZLD<span class="ml-2 text-sm text-slate-400">Zelira Therapeutics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.62</p><p class="text-xs font-semibold text-emerald-400">34.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Zelira Therapeutics Limited is a global biopharmaceutical company focused on the research, development, and commercialization of cannabinoid-based medicines. Operating primarily in Australia and the US, the company&#x27;s key products include ZENIVOL® for chronic insomnia and HOPE® for symptoms related to Autism Spectrum Disorder. Zelira pursues a strategy of clinical validation to develop proprietary IP for licensing and sale.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$7M</span><span class="text-blue-300">View analysis</span></div></a></div></section></div></main><footer class="border-t border-white/10 bg-ink-800/60"><div class="mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8"><div><h3 class="font-display text-lg font-semibold">ASX Desk</h3><p class="mt-3 text-sm text-slate-400">Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.</p><div class="mt-4 flex gap-3"><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button><button class="rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300">Download Media Kit</button></div></div><div class="grid grid-cols-2 gap-6 text-sm text-slate-400"><div><h4 class="mb-2 font-semibold text-slate-200">Platform</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/screener/">Screener</a></li><li><a class="hover:text-white" href="/news/">News &amp; Commentary</a></li><li><a class="hover:text-white" href="/about/">About</a></li></ul></div><div><h4 class="mb-2 font-semibold text-slate-200">Sectors</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/sectors/materials/">Materials</a></li><li><a class="hover:text-white" href="/sectors/financials/">Financials</a></li><li><a class="hover:text-white" href="/sectors/health care/">Health Care</a></li><li><a class="hover:text-white" href="/sectors/information technology/">Information Tech</a></li><li><a class="hover:text-white" href="/sectors/energy/">Energy</a></li></ul></div></div><div class="glass-card rounded-2xl p-6"><h4 class="font-semibold">Weekly Alpha Briefing</h4><p class="mt-2 text-sm text-slate-400">Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.</p><div class="mt-4 flex flex-col gap-3 sm:flex-row"><input type="email" placeholder="you@example.com" class="w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"/><button class="rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white">Subscribe</button></div><p class="mt-3 text-xs text-slate-500">By subscribing you agree to receive marketing updates. Unsubscribe anytime.</p></div></div><div class="border-t border-white/10 py-6 text-center text-xs text-slate-500"><p>General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.</p></div></footer></div><script src="/_next/static/chunks/webpack-04cc3a393714a88b.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/26d4368bf94c0ec4-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/media/36966cca54120369-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n3:HL[\"/_next/static/css/f5dc3b4b8467221e.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"4:I[5751,[],\"\"]\n6:I[231,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"362\",\"static/chunks/app/sectors/%5Bsector%5D/page-69ab854d38ad1414.js\"],\"\"]\n7:I[9275,[],\"\"]\n9:I[1343,[],\"\"]\na:I[8173,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"896\",\"static/chunks/896-78f6f35c40d7ae60.js\",\"185\",\"static/chunks/app/layout-24f8abeacb8025a3.js\"],\"Image\"]\nb:I[5864,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"896\",\"static/chunks/896-78f6f35c40d7ae60.js\",\"185\",\"static/chunks/app/layout-24f8abeacb8025a3.js\"],\"default\"]\nd:I[6130,[],\"\"]\n8:[\"sector\",\"health%20care\",\"d\"]\ne:[]\n"])</script><script>self.__next_f.push([1,"0:[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f5dc3b4b8467221e.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],[\"$\",\"$L4\",null,{\"buildId\":\"Foe7ts1ISHdRr1MzWVj0J\",\"assetPrefix\":\"\",\"initialCanonicalUrl\":\"/sectors/health%20care/\",\"initialTree\":[\"\",{\"children\":[\"sectors\",{\"children\":[[\"sector\",\"health%20care\",\"d\"],{\"children\":[\"__PAGE__?{\\\"sector\\\":\\\"health care\\\"}\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"sectors\",{\"children\":[[\"sector\",\"health%20care\",\"d\"],{\"children\":[\"__PAGE__\",{},[[\"$L5\",[\"$\",\"div\",null,{\"className\":\"space-y-10\",\"children\":[[\"$\",\"section\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"Sector\"}],[\"$\",\"h1\",null,{\"className\":\"mt-2 font-display text-3xl font-semibold\",\"children\":[\"health care\",\" Stocks\"]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-300\",\"children\":[\"Deep-dive coverage on ASX \",\"health care\",\" leaders, thematic trends, and relative performance signals. Our AI engine tracks earnings momentum, capital allocation, and sector rotation.\"]}],[\"$\",\"div\",null,{\"className\":\"mt-5 flex flex-wrap gap-3 text-xs text-slate-400\",\"children\":[[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":[166,\" stocks tracked\"]}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Updated daily\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"AI sector heatmaps\"}]]}]]}],[\"$\",\"section\",null,{\"className\":\"grid gap-6 lg:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Top Performers\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3\",\"children\":[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-400\",\"children\":\"Performance data is still being compiled for this sector.\"}]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Worst Performers\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3\",\"children\":[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-400\",\"children\":\"Performance data is still being compiled for this sector.\"}]}]]}]]}],[\"$\",\"section\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-2xl font-semibold\",\"children\":[\"All \",\"health care\",\" Coverage\"]}],[\"$\",\"div\",null,{\"className\":\"grid gap-6 md:grid-cols-2\",\"children\":[[\"$\",\"$L6\",null,{\"href\":\"/asx/CSL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CSL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"CSL Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"181.24\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-27.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$88.2B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/PNV\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PNV\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Polynovo Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.99\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-13.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$670M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/1AD\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"1AD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Adalta Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-25.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$11M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/1AI\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"1AI\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Algorae Pharmaceuticals Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"380.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Algorae Pharmaceuticals is an Australian drug discovery company utilizing its proprietary artificial intelligence platform, AlgoraeOS, to identify and develop novel therapeutic treatments. The company focuses on creating drug candidates for conditions with unmet medical needs, including dementia, cardiovascular disease, and Meniere's disease. Its business model is centered on leveraging AI to accelerate the traditionally lengthy and costly process of pharmaceutical research and development.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$34M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/4DX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"4DX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"4Dmedical Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"3.15\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"1066.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"4Dmedical Limited specializes in developing and commercializing state-of-the-art respiratory imaging technology, notably its XV Lung Ventilation Analysis Software (XV LVAS). This non-invasive technology provides quantitative and visual assessments of regional lung function, aiming to improve the diagnosis and management of various respiratory conditions. The company primarily operates in Australia and is aggressively expanding its presence in the large US healthcare market.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$1.9B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ACL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ACL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Australian Clinical Labs Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"2.73\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-8.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Australian Clinical Labs (ACL) is one of Australia's largest private pathology providers, offering a comprehensive range of services including blood tests, tissue analysis, and genetic testing. The company operates an extensive network of accredited laboratories and collection centres across the country, servicing general practitioners, medical specialists, and hospitals. ACL focuses on delivering accurate and timely diagnostic services to support patient care and clinical decision-making.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$515M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ACR\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ACR\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Acrux Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-33.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Acrux Limited is an Australian pharmaceutical company specialising in the development and commercialisation of topical and transdermal pharmaceutical products. Its flagship product, Estradiol Topical Solution (Evamist/Sprayon/Gynelle), is approved for treating moderate to severe vasomotor symptoms associated with menopause and is commercialised globally through licensing partnerships. The company leverages its proprietary formulation expertise to develop novel therapeutic solutions.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$6M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ACW\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ACW\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Actinogen Medical Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.04\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"40.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Actinogen Medical Limited (ASX: ACW) is an Australian clinical-stage biotechnology company focused on developing treatments for neurological and psychiatric disorders. Its lead compound, Xanamem, is an orally administered small molecule designed to inhibit the enzyme 11β-HSD1, which plays a role in cognitive dysfunction associated with diseases like Alzheimer's and depression. The company operates globally with its primary research and development activities in Australia and the US.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$153M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ADR\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ADR\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Adherium Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-54.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Adherium Limited develops digital health solutions focused on improving medication adherence and outcomes for chronic respiratory diseases, primarily asthma and COPD. Their flagship Hailie® platform integrates connected medical devices, such as smart inhalers, with software and data analytics to monitor medication usage and provide patient insights. The company aims to partner with pharmaceutical companies and healthcare providers globally to commercialise its technology.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$12M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ADO\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ADO\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Anteotech Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"8.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Anteotech Ltd is an Australian surface chemistry technology company developing and commercialising its proprietary 'Anteo' platform. The company operates across two high-growth sectors: the energy division focuses on 'AnteoX', a high-performance binder additive for lithium-ion batteries, while the life sciences division leverages its 'Anteobind' technology to improve the performance of diagnostic tests and other medical applications.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$40M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AFP\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AFP\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Aft Pharmaceuticals Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"3.10\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"34.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Aft Pharmaceuticals Limited is a New Zealand-based specialty pharmaceutical company focused on the development, licensing, and distribution of a broad range of innovative over-the-counter (OTC) and prescription products. Its flagship product, Maxigesic, a proprietary pain relief medication, is central to its international expansion strategy across Australia, New Zealand, Asia, Europe, and the US.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$325M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AGN\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AGN\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Argenica Therapeutics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.29\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-61.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Argenica Therapeutics Limited (ASX: AGN) is an Australian biotechnology company focused on developing novel therapeutics for neurological conditions, primarily stroke. Their lead product candidate, ARG-007, aims to reduce brain tissue damage and improve patient outcomes after an ischaemic stroke, addressing a significant unmet medical need.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$37M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AHC\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AHC\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Austco Healthcare Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.38\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"28.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Austco Healthcare Limited (ASX: AHC) is a global developer and supplier of critical communication and nurse call technology solutions for the healthcare sector. The company primarily serves hospitals, aged care facilities, and other healthcare environments, providing advanced IP-based nurse call systems and integrated communication platforms. AHC operates internationally with a significant presence across Australia, North America, the UK, and the Middle East.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$139M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AHE\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AHE\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Adheris Health Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"0.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Adheris Health Limited (ASX: AHE) operates within the health care equipment and services sector in Australia, focusing on patient engagement solutions through its proprietary platform, aiding in medication adherence. Primarily serving healthcare providers and pharmaceutical companies, AHE’s key offerings include personalized patient support programs. Headquartered in Australia, it serves the APAC region.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$13M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AHX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AHX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Apiam Animal Health Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.87\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"123.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Apiam Animal Health Limited is a leading provider of veterinary services, operating a network of clinics predominantly across regional and rural Australia. The company offers a comprehensive range of veterinary care for companion animals, equine, and livestock, along with related products and services.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$160M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ALA\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ALA\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Arovella Therapeutics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.09\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"17.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Arovella Therapeutics Limited (ALA) is an Australian biotechnology company focusing on developing innovative therapies, particularly in the oncology and rare diseases spaces. Operating primarily out of Australia, ALA leverages cutting-edge research to bring potential life-changing treatments to global markets. Key products/services include its proprietary drug candidates in various clinical trial phases.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$114M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ALC\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ALC\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Alcidion Group Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.10\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"28.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Alcidion Group Limited is a healthcare technology company that develops and markets software solutions designed to improve patient care and operational efficiency in hospitals and healthcare organizations. Operating primarily in the UK, Australia, and New Zealand, their key products include the Miya Precision platform, which offers electronic medication management (Better Meds), patient flow, and clinical decision support systems.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$148M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AN1\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AN1\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Anagenics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-25.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Anagenics Limited (ASX: AN1) is an Australian biotechnology company focused on developing and commercialising solutions for hair loss and hair regrowth. Operating primarily in the health care sector, the company aims to address unmet needs in the global hair care market through scientific research and proprietary product development.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$3M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ANR\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ANR\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Anatara Lifesciences Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"71.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Anatara Lifesciences Ltd (ASX: ANR) is an Australian biotechnology company focused on developing and commercializing novel treatments for gastrointestinal diseases in humans and animals. Operating primarily from Australia, its key product is Anatara's CIC therapy for carbohydrate malabsorption. The company also explores veterinary applications.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$3M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ANN\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ANN\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Ansell Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"32.37\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-4.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Ansell Limited is a global leader in providing superior health and safety protection solutions that enhance human well-being. The company designs, develops, and manufactures a wide range of protection solutions, primarily surgical, examination, and industrial gloves, as well as protective body suits. Ansell operates globally with a strong presence in both the healthcare and industrial sectors, supported by well-known brands like Gammex, Microflex, and AlphaTec.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$4.7B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ARX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ARX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Aroa Biosurgery Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.67\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"57.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Aroa Biosurgery Limited (ASX: ARX) develops and commercializes surgical biomaterials in the global healthcare sector, focusing on advanced wound care and surgical procedures. Based in Auckland, New Zealand, with listing on the ASX, its key products include Absorbable Puteon and other bioactive surgical implants. Operating primarily in Australia, New Zealand, and expanding into North America.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$235M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AT1\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AT1\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Atomo Diagnostics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.04\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"135.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Atomo Diagnostics Limited (ASX: AT1) is an Australian medical device company specialising in the design, manufacture, and commercialisation of user-friendly rapid diagnostic test (RDT) devices. Its patented AtomoRapid platform simplifies blood-based point-of-care and self-test applications, aiming to improve testing accuracy and accessibility for various infectious diseases globally.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$34M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ATH\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ATH\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Alterity Therapeutics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"0.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Alterity Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. Headquartered in Melbourne, Australia, the company's lead candidate, ATH434, is a small molecule drug designed to treat Multiple System Atrophy (MSA) and other Parkinsonian disorders by restoring the brain's normal iron balance. Alterity is advancing ATH434 through global clinical trials to address the high unmet medical need in these conditions.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$87M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ATX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ATX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Amplia Therapeutics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.13\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"78.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Amplia Therapeutics Limited is an Australian clinical-stage biotechnology company focused on developing novel treatments for cancer and fibrosis. The company is advancing small molecule inhibitors, including AMP945 (a FAK inhibitor) and AMP880 (a p38 MAPK inhibitor), with lead programs targeting pancreatic cancer and idiopathic pulmonary fibrosis.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$67M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AVE\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AVE\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Avecho Biotechnology Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"100.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Avecho Biotechnology Limited (ASX: AVE) operates in Australia, specializing in the development of innovative therapeutic products for unmet medical needs. Focused on proprietary formulations and delivery technologies for existing drugs, improving efficacy and patient outcomes. Key product pipeline: Novel formulations for pain management and neurology.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$33M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AVH\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AVH\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Avita Medical Inc.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"1.14\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-58.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Avita Medical Inc. is a regenerative medicine company developing and commercialising the RECELL System, a medical device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of a patient’s own skin. This innovative technology is primarily used for the treatment of acute thermal burns, with expanding applications in vitiligo and reconstructive procedures, and its commercial operations are predominantly focused in the United States.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$186M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AVR\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AVR\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Anteris Technologies Global Corp.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"7.80\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"20.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Anteris Technologies Global Corp. (ASX: AVR) is an Australian-based medical device company focused on structural heart disease. They are developing the DurAVR™ Transcatheter Aortic Valve Replacement (TAVR) system, which incorporates their proprietary ADAPT® anti-calcification tissue technology designed to enhance valve durability and improve patient outcomes for severe aortic stenosis.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$813M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AYA\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AYA\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Artrya Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"3.38\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"350.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Artrya Limited is an Australian medical technology company that develops and commercializes AI-powered software for the diagnosis of coronary artery disease. Its flagship product, Salix, analyzes cardiac CT scans to identify stenosis and vulnerable plaque, aiming to improve diagnostic accuracy and prevent heart attacks. The company targets cardiologists, radiologists, and hospitals globally, with key regulatory approvals in Australia, Europe, and the USA.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$547M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/BB1\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"BB1\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Blinklab Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.94\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"144.2\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Blinklab Limited (ASX: BB1) is a Australian health tech company, operating in the health care equipment and services sector. Specific to the Australian market, it develops innovative, non-invasive diagnostic devices for early detection of ophthalmological conditions, leveraging AI-driven analysis. Key product is 'EyeSightAI', targeting the Australian healthcare system and private clinics.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$124M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/BDX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"BDX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Bcal Diagnostics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.12\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"12.2\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Bcal Diagnostics Limited (ASX: BDX) is an Australian biotechnology company focused on developing a novel, non-invasive blood test for the early detection of breast cancer, named the Bcal™ test. Leveraging specific lipid biomarkers, their technology aims to provide a more accessible and accurate screening tool, initially targeting the Australian market with global commercialisation ambitions.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$42M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/BIT\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"BIT\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Biotron Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.00\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-14.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Biotron Limited is a clinical-stage biotechnology company based in Australia, focused on the development of novel antiviral drugs targeting a range of significant diseases. Its lead compound, BIT225, is in clinical development for the treatment of HIV-1, aiming to eradicate the virus from reservoirs in the body. The company's research also extends to other viruses, including Hepatitis C and, more recently, coronaviruses.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$8M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/BMT\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"BMT\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Beamtree Holdings Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.18\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-23.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Beamtree is a healthcare technology company specialising in clinical decision support and health data analytics. It provides software-as-a-service (SaaS) solutions, such as its PICQ and RippleDown platforms, to hospitals and health services to automate clinical record classification, improve data quality, and support diagnostic decisions. The company primarily operates in Australia with a growing international presence, aiming to improve administrative efficiency and patient outcomes.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$49M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/BP8\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"BP8\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Bph Global Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.00\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-14.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Bph Global Ltd (ASX: BP8) is an Australian-based biotechnology company focused on the early-stage research and development of novel therapeutic compounds. The company primarily targets unmet medical needs within specific disease areas, aiming to advance promising drug candidates through pre-clinical and early clinical trial phases. BP8 operates as a lean R\u0026D entity, leveraging scientific partnerships to progress its pipeline.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$4M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/BOT\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"BOT\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Botanix Pharmaceuticals Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.12\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-73.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Botanix Pharmaceuticals is a clinical-stage dermatology company focused on developing and commercializing treatments for common skin conditions. Its lead product, Sofdra™ (sofpironium bromide gel, 12.45%), recently received FDA approval for the treatment of excessive underarm sweating (primary axillary hyperhidrosis). The company leverages its proprietary Permetrex™ skin delivery technology for its product pipeline, which also includes candidates for rosacea and acne.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$227M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CAN\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CAN\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Cann Group Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-68.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Cann Group Limited is a pioneering Australian medicinal cannabis company focused on the breeding, cultivation, and manufacturing of cannabis for medical and research purposes. Operating primarily from its large-scale, state-of-the-art facility in Mildura, Victoria, the company produces a range of GMP-certified dried flower and oil-based products for supply to patients in Australia and for export markets.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$13M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CBL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CBL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Control Bionics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.06\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"31.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Control Bionics Limited (ASX: CBL) is a healthcare equipment and services company operating in Australia, focusing on the development and distribution of innovative assistive technologies. Key products include customizable, speech-generating devices for individuals with severe speech and language impairments. Founded in 2016 and listed on the ASX in December 2020.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$25M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CC5\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CC5\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Clever Culture Systems Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.03\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"107.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Clever Culture Systems Limited (CC5) is an Australian healthcare equipment and services company developing innovative cell culture solutions for the biotechnology and pharmaceutical industries. Operating primarily in Australia, with potential expansion to APAC regions, its key product is the Clever Culture SystemTM, designed to enhance cell growth and efficiency in research and production settings.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$61M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CGS\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CGS\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Cogstate Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"2.16\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"55.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Cogstate Ltd (ASX: CGS) is a health technology company providing innovative brain health solutions, including cognitive testing and assessment tools, operating globally with a strong presence in Australia and the USA. Key products include its proprietary cognitive assessment technologies used in clinical trials, research, and healthcare. Its platform is utilized by pharmaceutical companies, academic institutions, and healthcare providers to measure cognitive function in various neurological and psychiatric conditions.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$374M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CHM\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CHM\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Chimeric Therapeutics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.00\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-60.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Chimeric Therapeutics is a clinical-stage cell therapy company focused on developing and commercialising novel treatments for cancer. The company's pipeline includes both autologous and allogeneic ('off-the-shelf') CAR T and CAR NK cell therapies. Its lead assets are CHM 1101 (CLTX CAR T) for glioblastoma and CHM 2101 (CDH17 CAR T) for gastrointestinal cancers, with clinical trials being conducted in the United States.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$9M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CMB\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CMB\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Cambium Bio Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.59\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"93.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Cambium Bio Limited is an Australian clinical-stage biotechnology company focused on developing novel regenerative medicine therapies. Its lead program is centered on a proprietary cell-based treatment for osteoarthritis, aiming to repair damaged cartilage and reduce inflammation. The company's operations are primarily focused on preclinical research and advancing its lead candidate into early-stage human clinical trials.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$14M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CMP\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CMP\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Compumedics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.35\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"1.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Compumedics Limited is an Australian medical device company specializing in the development and sale of diagnostic technology for sleep disorders, neurology, and brain research. The company operates globally, with key products including laboratory-based and wearable sleep monitoring systems (Somfit), neuro-diagnostic equipment (Neuroscan), and advanced magnetoencephalography (MEG) brain imaging systems.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$75M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/COH\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"COH\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Cochlear Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"258.74\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-1.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Cochlear Limited is a global medical device company that designs, manufactures, and supplies implantable hearing solutions, including cochlear implants, bone conduction implants, and acoustic implants. Operating worldwide, the company helps individuals with moderate to profound hearing loss, maintaining a dominant market position in its specialized field.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$17.0B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/COV\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"COV\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Cleo Diagnostics Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.60\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"71.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Cleo Diagnostics Ltd (COV) is an ASX-listed life sciences company focused on developing diagnostic solutions, primarily operating in Australia. Its key products/services include novel point-of-care and lab-based diagnostic technologies for infectious diseases. COV is in the pre-commercialization phase, with a focus on R\u0026D.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$86M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CQT\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CQT\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Conneqt Health Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.04\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"32.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Conneqt Health Limited is an Australian digital health company providing an integrated platform that connects consumers, healthcare providers, and payers. Its core products include MyHealth1st, an online healthcare booking marketplace, and Visionflex, a telehealth hardware and software solution. The company aims to improve access to healthcare and streamline administrative processes for clinics, governments, and corporate clients across Australia.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$28M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CSX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CSX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Cleanspace Holdings Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.65\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"39.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"CleanSpace Holdings Limited designs, manufactures, and sells advanced respiratory protection equipment. The company's core products are compact and lightweight Powered Air Purifying Respirators (PAPRs) used by healthcare professionals and industrial workers globally to protect against airborne contaminants and infectious diseases.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$51M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CTE\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CTE\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Cryosite Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"1.10\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"38.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Cryosite Limited is an Australian company specializing in two main areas: private cord blood and tissue banking for families, and outsourced clinical trial logistics, biological storage, and cryo-preservation services for the biotechnology and pharmaceutical industries. Operating from its TGA-licensed facility in Sydney, the company provides critical temperature-controlled storage and distribution solutions for high-value biological materials.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$54M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CTQ\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CTQ\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Careteq Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-26.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Careteq Limited (ASX: CTQ) is a health care company focused on developing and providing innovative health care equipment and services, operating primarily in Australia. Key products/services include personalized aged care solutions and assistive technology. With a specific focus on the aging population, CTQ offers smart home automation systems for elderly care facilities.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$3M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CU6\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CU6\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Clarity Pharmaceuticals Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"2.89\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"37.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Clarity Pharmaceuticals is an Australian radiopharmaceutical company focused on developing innovative diagnostic and therapeutic products for cancer using copper isotopes. Its proprietary 'Theranostics' platform targets cancers such as prostate cancer (with SAR-bisPSMA) and neuroblastoma (with SARTATE), with lead candidates currently in advanced global clinical trials.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$1.0B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CVB\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CVB\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Curvebeam Ai Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.08\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-36.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Curvebeam Ai Limited (ASX: CVB) is a medical technology company specializing in the design and manufacture of weight-bearing CT imaging systems for extremities. Their proprietary systems, such as the HiRise and PedCat, integrate AI capabilities to provide high-resolution 3D images that aid in the diagnosis and treatment of orthopedic and podiatric conditions. Operating globally, the company aims to improve clinical outcomes through advanced diagnostic imaging.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$38M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CUV\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CUV\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Clinuvel Pharmaceuticals Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"11.73\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"2.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Clinuvel Pharmaceuticals is a global biopharmaceutical company focused on developing and commercialising treatments for patients with severe genetic and skin disorders. Its lead product, SCENESSE® (afamelanotide), is the world's first systemic photoprotective drug approved for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP) across Europe, the USA, and Australia. The company is actively pursuing the expansion of SCENESSE® into new indications with larger patient populations, such as vitiligo.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$592M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CYC\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CYC\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Cyclopharm Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.93\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-19.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Cyclopharm Limited (ASX: CYC) is an Australian-based company specializing in nuclear medicine products. Its flagship product, TechneGas (marketed as TechneLite in some regions), is a lung ventilation imaging agent used primarily for the diagnosis of pulmonary embolism. The company operates globally, with a significant focus on commercialising TechneGas in major markets like the United States following recent regulatory approvals.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$107M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CYP\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CYP\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Cynata Therapeutics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.34\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"86.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Cynata Therapeutics Limited (ASX: CYP) is an Australian biotechnology company focused on developing innovative cellular therapies for serious diseases using its proprietary Cell Control Technology. Operating primarily in the Australian market with research collaborations globally, its key product in development is rCTRM, a mesenchymal stromal cell therapy for acute respiratory distress syndrome (ARDS) and other inflammatory conditions.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$83M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/DOC\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"DOC\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Doctor Care Anywhere Group Plc\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.14\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"52.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Doctor Care Anywhere is a UK-founded digital health company providing virtual GP consultations and other telehealth services. It operates primarily on a B2B2C model, partnering with major insurers, like AXA Health, and corporate clients to offer its 24/7 platform to their members and employees. The company's core service allows patients to book and attend video or phone appointments with doctors for diagnostics, prescriptions, and specialist referrals.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$59M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/DVL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"DVL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Dorsavi Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.04\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"500.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Dorsavi Ltd (ASX: DVL) is an Australian-based company that develops wearable sensor technology and software solutions for analyzing human movement. Their proprietary technology provides objective data for injury prevention, performance enhancement, and clinical rehabilitation across elite sports, occupational health, and healthcare sectors, operating globally.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$43M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/DXB\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"DXB\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Dimerix Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.52\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"24.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Dimerix Limited is an Australian clinical-stage biotechnology company focused on developing innovative new therapies for kidney and inflammatory diseases. Its lead candidate, DMX-200, is currently in a global Phase 3 clinical trial for Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney disorder. The company's pipeline leverages its proprietary G protein-coupled receptor (GPCR) technology.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$315M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/EBO\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"EBO\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Ebos Group Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"22.15\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-36.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Ebos Group Limited (EBO) is a leading provider of medical and surgical products and services in Australia and New Zealand. Operating across both countries, EBO supplies a broad range of healthcare solutions including medical equipment, pharmaceuticals, and diagnostic products to hospitals, private practices, and retail pharmacies. A key focus is on distributing products from international manufacturers to the Australasian market.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$4.5B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/EBR\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"EBR\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Ebr Systems Inc.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.76\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-56.9\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Ebr Systems is a US-based medical device company developing the world's only wireless, inside-the-heart (endocardial) pacing system for cardiac resynchronization therapy (CRT). Their lead product, the WiSE™ system, is designed to treat heart failure patients who have not responded to traditional CRT methods or are unsuitable for them. The company is primarily focused on gaining US Food and Drug Administration (FDA) approval for WiSE, with its pivotal SOLVE-CRT clinical trial being the key value driver.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$347M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ECS\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ECS\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Ecs Botanics Holdings Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-61.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Ecs Botanics Holdings Ltd (ASX: ECS) operates in the Health Care sector, focusing on Pharmaceuticals, Biotechnology, and Life Sciences. Based in Australia, the company specializes in the development and commercialization of cannabinoid-based health products. Key offerings include CBD-infused wellness products and cannabis for medical use, primarily targeting the Australian and New Zealand markets.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$10M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/EMD\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"EMD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Emyria Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.05\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"74.2\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Emyria Limited is a data-backed clinical drug development company operating in Australia. It runs a network of specialist medical clinics (Emerald Clinics) that gather proprietary Real-World Evidence from patients using unregistered medicines like cannabinoids. This data is then used to develop its own drug candidates and advance its programs in psychedelic-assisted therapies, most notably an MDMA-assisted therapy program for Post-Traumatic Stress Disorder (PTSD).\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$47M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ENL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ENL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Enlitic Inc.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-85.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Enlitic Inc. (ASX: ENL), listed as of December 19, 2023, is a micro-cap Health Care company focused on developing artificial intelligence (AI) driven diagnostic tools for the medical imaging sector, primarily operating in Australia with ambitious global expansion plans. Key products/services include AI-powered imaging analysis software for healthcare providers. Given its early listing stage, specific operational details are limited but the company aims to disrupt traditional diagnostic processes with machine learning algorithms.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$9M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/EMV\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"EMV\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Emvision Medical Devices Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"1.75\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-17.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Emvision Medical Devices Ltd (ASX: EMV) is an Australian medical device company developing a portable brain scanner based on electromagnetic microwave technology. Their primary focus is on providing rapid and accessible diagnosis of stroke in various settings, from ambulances to remote clinics, aiming to improve patient outcomes through early detection. The company targets global markets for its innovative diagnostic solution.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$168M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ENP\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ENP\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Entropy Neurodynamics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.03\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-6.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Entropy Neurodynamics Limited (ASX: ENP) is an Australian biotechnology company focused on the research and development of novel therapeutic solutions for complex neurological disorders. Leveraging advanced neurodynamic principles, the company aims to address significant unmet medical needs in areas such as neurodegenerative diseases and neuropsychiatric conditions through its pipeline of proprietary drug candidates.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$52M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/EPI\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"EPI\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Epiminder Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.78\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-23.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Epiminder Limited (ASX: EPI) is a Australian health tech company providing AI-driven medical reminders and adherence solutions for patients with chronic conditions, operating primarily in the Australian healthcare market. Their key product is the Epiminder Platform, which offers personalized medication reminders and health tracking. As a small-cap company, its operations are focused on the Australian market with potential for expansion into broader APAC regions.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$171M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/EPN\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"EPN\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Epsilon Healthcare Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.03\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"37.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Epsilon Healthcare Limited (EPN) was an Australian pharmaceutical company primarily engaged in the cultivation, manufacturing, and distribution of medicinal cannabis products, focusing on B2B and white-label services. Operating a TGA-licensed facility in Southport, Queensland, the company aimed to supply both domestic and international markets. However, the company faced significant financial challenges, leading to its delisting from the ASX on 1 March 2024 following administration.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$11M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/EYE\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"EYE\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Nova Eye Medical Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.17\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"70.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Nova Eye Medical Limited (ASX: EYE) develops and markets innovative ocular (eye) care medical devices and services, primarily operating within Australia and expanding into APAC regions. Key products include the iStent device for glaucoma treatment and proprietaryLASIK surgery technologies. Their services extend to ophthalmic clinical trial management and eye care clinics.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$50M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/FCG\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"FCG\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Freedom Care Group Holdings Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.04\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"0.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Freedom Care Group Holdings Limited (FCG) is an Australian provider of in-home care services, primarily supporting individuals under the National Disability Insurance Scheme (NDIS) and those requiring aged care. The company aims to empower clients to live independently in their own homes by delivering personalised care plans and support services across various regions in Australia.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$-1\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/FPH\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"FPH\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Fisher \u0026 Paykel Healthcare Corporation Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"33.87\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"12.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Fisher \u0026 Paykel Healthcare is a global leader in designing, manufacturing, and marketing products and systems for use in acute and chronic respiratory care, sleep apnea treatment, and surgical applications. Headquartered in New Zealand and dual-listed on the ASX, the company operates across more than 120 countries, primarily serving hospitals and home care providers worldwide with innovative medical devices.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$20.0B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/FRE\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"FRE\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Firebrick Pharma Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.06\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-29.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Firebrick Pharma Limited (ASX: FRE) is an Australian pharmaceutical company focused on developing novel antiviral therapies for common viral infections. Its lead product, Nasodine, is a broad-spectrum topical antiviral specifically targeting the common cold, currently undergoing Phase 3 clinical trials in the United States.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$16M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/GLH\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"GLH\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Global Health Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.07\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-36.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Global Health Limited (GLH), listed on the ASX since April 4, 2000, is a healthcare technology company operating primarily in Australia. It specializes in developing and implementing digital health solutions, including telehealth platforms and electronic health record (EHR) systems for healthcare providers and patients across the country. Key products include its myhealthrecord and Telehealth platforms designed for Australian healthcare standards.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$5M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/GSS\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"GSS\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Genetic Signatures Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.14\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-71.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Genetic Signatures Limited (ASX: GSS) is an Australian molecular diagnostics company specializing in rapid detection solutions for infectious diseases. Leveraging its proprietary 3Base™ technology, GSS develops and commercializes diagnostic kits for identifying pathogens in areas such as gastrointestinal, respiratory, and sexual health, primarily for pathology laboratories and hospitals globally.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$33M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/GTG\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"GTG\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Genetic Technologies Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.04\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"0.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Genetic Technologies Limited (ASX: GTG) is a biotechnology company focused on the development of genomics-based technologies for the prevention, diagnosis, and treatment of various diseases. Primarily operating in Australia, with potential global reach through partnerships, GTG has key products/services including diagnostic tools and therapies leveraging genetic insights. Specifically, it has developed the Ovarian Cancer Test and the Breast Cancer Test, utilizing DNA methylation biomarkers for early detection.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$-1\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/HIQ\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"HIQ\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Hitiq Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-54.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Hitiq Limited (ASX: HIQ) is a health care equipment and services company listed on the Australian Stock Exchange since June 16, 2021. Primarily operating in Australia, HIQ focuses on developing and commercializing innovative medical devices for Diagnostic Imaging and Interventional Radiology, with a key product being its proprietary AI-driven Imaging Analysis Software. The company aims to enhance patient outcomes through advanced imaging solutions.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$9M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/HLS\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"HLS\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Healius Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.92\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-34.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Healius Limited is one of Australia's largest healthcare companies, providing extensive services in pathology, diagnostic imaging, and day hospitals. Operating a national network of collection centres, laboratories, and imaging sites, the company is a key player in the country's diagnostic services landscape. Its core brands include Dorevitch Pathology, QML Pathology, Laverty Pathology, and Lumus Imaging.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$683M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/HMD\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"HMD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Heramed Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.04\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"110.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Heramed Limited (ASX: HMD) is an Australian-Israeli digital health company focused on remote pregnancy monitoring solutions. Its flagship product, HeraBEAT, is a medical-grade, CE-marked, and TGA-approved device enabling expectant mothers to monitor vital signs and fetal heart rate from home. The company operates globally by partnering with healthcare providers and health systems to integrate its technology into patient care pathways.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$49M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/HXL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"HXL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Hexima Limited.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"0.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Hexima Limited (HXL), listed on the ASX since 01/12/2020, focuses on the development of innovative biotechnological solutions within the health care sector, specifically targeting novel therapeutic approaches in the pharmaceuticals and life sciences space. Operating out of Australia, the company's primary activities involve research and development of biologic products, though specific flagship products are currently under wraps due to its early listing stage. As a biotech firm, its operations are primarily R\u0026D-centric.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$-1\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IBX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IBX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Imagion Biosystems Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.03\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"62.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Imagion Biosystems Limited is a clinical-stage biotechnology company developing non-radioactive imaging technology for early cancer detection. Its proprietary MagSense® platform uses magnetic nanoparticles to pinpoint cancer cells, with its lead program targeting HER2 breast cancer to improve staging accuracy and treatment decisions. The company operates primarily in Australia and the United States, focusing on advancing its technology through human clinical trials.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$12M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ICR\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ICR\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Intelicare Holdings Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.03\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"316.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Intelicare Holdings Limited (ASX: ICR) is an Australian technology company specializing in AI-powered assistive living solutions for the aged care and disability support sectors. Its flagship InteliCare platform uses sensors and artificial intelligence to monitor the well-being of individuals remotely, providing insights to carers and family members without invasive surveillance. The company primarily operates within the Australian market, aiming to improve independent living outcomes.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$16M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IDX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IDX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Integral Diagnostics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"2.49\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"8.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Integral Diagnostics Limited (ASX: IDX) is a leading provider of diagnostic imaging services across Australia. The company operates an extensive network of radiology clinics offering a comprehensive range of services, including MRI, CT, ultrasound, X-ray, and nuclear medicine, to both public and private patients. IDX focuses on delivering high-quality patient care through advanced technology and highly skilled medical professionals in metropolitan and regional areas.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$936M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IDT\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IDT\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Idt Australia Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.05\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-51.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Idt Australia Limited is an Australian pharmaceutical contract development and manufacturing organisation (CDMO) based in Boronia, Victoria. The company provides a full range of services from early-stage drug development and clinical trial material manufacturing to commercial scale production of finished drug products. IDT operates TGA and FDA-inspected facilities, specialising in high-containment active pharmaceutical ingredients (APIs) and sterile injectables.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$20M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ILA\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ILA\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Island Pharmaceuticals Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.41\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"151.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Island Pharmaceuticals Limited (ASX: ILA) is an early-stage Australian biotechnology company focused on the research, development, and commercialization of innovative therapeutic solutions in the pharmaceuticals and biotechnology sector. Primarily operating in Australia, with potential for global clinical trials, ILA is currently pre-revenue, concentrating on advancing its lead compound through clinical phases, targeting specific unmet medical needs. Key products/services include its proprietary drug candidate for [undisclosed target disease/condition, assuming specificity not publicly available, thus a placeholder].\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$113M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IIQ\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IIQ\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Inoviq Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.34\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-17.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Inoviq Ltd is an Australian biotechnology company developing and commercializing next-generation diagnostics and exosome-based therapeutics for cancer. Its core technologies include the EXO-NET platform for exosome isolation and the SubB2M platform for developing blood tests for early cancer detection. The company's lead programs are focused on developing non-invasive tests for ovarian and breast cancer.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$48M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IMC\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IMC\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Immuron Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.03\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-52.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Immuron Limited (ASX: IMC) is an Australian biopharmaceutical company focused on the development and commercialisation of oral immunotherapies for the treatment of gut-mediated diseases. The company's key assets include Travelan, an over-the-counter product for the prevention of traveler's diarrhea, and IMM-124E, a lead prescription drug candidate currently in clinical development for liver diseases such as Non-Alcoholic Steatohepatitis (NASH) and Alcoholic Steatohepatitis (ASH). Immuron operates globally through distribution agreements for Travelan while advancing its drug pipeline.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$10M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IMM\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IMM\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Immutep Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.38\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"35.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Immutep Limited (ASX: IMM) is a biopharmaceutical company headquartered in Australia, specializing in immunotherapy for cancer and auto-immune diseases. It operates globally with research alliances and trials in the US and Europe. Key product is pep005, an immune-stimulating agent, and ipilimumab combination therapies. IMM has no commercial products yet, focusing on clinical trials.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$567M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IME\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IME\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Imexhs Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.47\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"17.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Imexhs Limited is a medical imaging software and services provider offering cloud-based Radiology Information Systems (RIS) and Picture Archiving and Communication Systems (PACS) via its HIRUKO platform. The company primarily operates in Latin America, serving hospitals and clinics with a recurring revenue, Software-as-a-Service (SaaS) model. It also provides remote teleradiology services where its radiologists interpret medical images for clients.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$25M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IMU\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IMU\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Imugene Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.26\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-76.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Imugene Limited is an Australian clinical-stage immune-oncology company developing a range of novel cancer immunotherapies to activate the body’s immune system against cancer. Their pipeline focuses on oncolytic viruses (like VAXINIA) and B-cell immunotherapies (such as PD1-Vaxx and HER-Vaxx) for various solid tumors and blood cancers.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$85M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IMR\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IMR\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Imricor Medical Systems Inc.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"1.92\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"39.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Imricor Medical Systems (IMR) is a medical device company pioneering real-time iCMR (interventional cardiac magnetic resonance) ablation procedures. The company designs, manufactures, and sells systems, including its flagship Advantage-MR EP Recorder and Vision-MR Ablation Catheter, which allow cardiologists to perform cardiac ablations inside an MRI scanner. This provides real-time 3D visualisation of the heart and ablations without the ionising radiation used in traditional x-ray guided procedures, with commercial operations currently focused in Europe.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$613M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IPD\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IPD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Impedimed Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-53.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Impedimed Limited (ASX: IPD) is a medical technology company specializing in bioimpedance spectroscopy (BIS) technology. They develop and market devices, notably the SOZO digital health platform with L-Dex, for the early detection and management of lymphedema in cancer survivors and for general fluid status assessment. The company primarily operates globally, with a strong focus on market penetration in the United States healthcare sector.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$43M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IRX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IRX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Inhalerx Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-7.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Inhalerx Limited (ASX: IRX) is an Australian health technology company focused on the development and commercialisation of innovative drug delivery systems, primarily within the respiratory health sector. The company aims to improve therapeutic outcomes for patients with chronic respiratory conditions through novel inhaler technologies and enhanced medication delivery.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$5M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IVG\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IVG\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Invert Graphite Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.03\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"0.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Invert Graphite Limited (IVG) is an ASX-listed life sciences company focused on the development of graphene-based technologies for pharmaceutical applications, primarily operating in Australia with a growing presence in Asia-Pacific. Key products/services include graphene-enhanced drug delivery systems. The company leverages its proprietary technology to improve efficacy and reduce side effects of existing medications.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$13M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IVX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IVX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Invion Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.08\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-17.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Invion Limited (IVX) is an Australian biotechnology company dedicated to developing novel inhaled therapies for inflammatory and autoimmune diseases. Its primary focus is on advancing its lead drug candidate, IVX-Z001 (formerly INV102/Nadirad), which targets conditions such as idiopathic pulmonary fibrosis (IPF) and severe asthma. The company aims to address significant unmet medical needs through its therapeutic pipeline.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$7M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/IXC\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"IXC\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Invex Therapeutics Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.13\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"83.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Invex Therapeutics is a clinical-stage biopharmaceutical company focused on repurposing the drug Exenatide (under the brand name Presendin™) for neurological conditions associated with raised intracranial pressure. The company's primary focus is its pivotal Phase III clinical trial, IIH Evolve, for the treatment of Idiopathic Intracranial Hypertension (IIH), a condition with a significant unmet medical need.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$9M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/LDX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"LDX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Lumos Diagnostics Holdings Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.26\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"983.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Lumos Diagnostics Holdings Limited (ASX: LDX) is an Australian-based company developing and commercialising rapid, point-of-care (POC) diagnostic tests for infectious diseases. Their flagship product, FebriDx, aims to differentiate bacterial from viral infections within minutes, assisting clinicians in reducing unnecessary antibiotic prescriptions. Lumos operates globally with R\u0026D and manufacturing facilities in the US, targeting healthcare markets across North America, Europe, and Australia.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$214M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/LGP\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"LGP\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Little Green Pharma Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.13\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"0.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Little Green Pharma Ltd (ASX: LGP) is an Australian-based medicinal cannabis company focused on the cultivation, manufacturing, and global distribution of high-quality medicinal cannabis products. The company operates vertically integrated facilities and supplies a range of cannabis oils and dried flower products to patients in Australia and key international markets, primarily across Europe.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$37M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/LTP\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"LTP\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Ltr Pharma Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.51\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"10.9\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Ltr Pharma Limited (ASX: LTP) is a clinical-stage biotechnology company focused on developing innovative treatments for rare and underserved medical conditions. Operating primarily in Australia with research partnerships internationally, its key product is LTP-101, a novel oral therapeutic for Pulmonary Arterial Hypertension (PAH). The company leverages Australian research institutions for preclinical studies.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$92M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/M7T\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"M7T\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Mach7 Technologies Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.39\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"14.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Mach7 Technologies Limited (M7T) is an Australian company operating in the health care sector, providing medical imaging and informatics solutions to hospitals and healthcare providers globally, with a strong focus on interoperability and data integration. Key products include the Mach7 Dead Pixel, Mach7 ImageView, and Mach7 Data Integrity tools designed to enhance image management and workflow efficiency. Listed on the ASX since 2005, M7T serves clients across Australia, the United States, and internationally.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$94M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/MAP\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"MAP\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Microba Life Sciences Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.09\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-57.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Microba Life Sciences Limited (ASX: MAP) is an Australian life sciences company focused on the human gut microbiome. They leverage their proprietary high-resolution microbiome analysis technology to develop both diagnostic services and novel therapeutic products. Their key offerings include the Microba Insight™ diagnostic test for gut health analysis and a pipeline of microbiome-based therapeutic candidates targeting various chronic diseases.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$53M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/MEM\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"MEM\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Memphasys Limited.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-22.2\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Memphasys Limited (ASX: MEM) is a biotechnology company focusing on developing innovative medical devices, notably the MemProsys platform, aimed at improving sperm selection for assisted reproductive technologies. Primarily operating in Australia, with potential for global market expansion, key products/services include proprietary microfluidic devices for fertility treatments. Based in Melbourne, Australia, with research and development efforts concentrated domestically.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$19M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/MSB\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"MSB\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Mesoblast Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"2.39\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"21.9\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Mesoblast Limited (ASX: MSB) is an Australian-based biotechnology company focused on developing allogeneic mesenchymal stromal cell (MSC) therapies for inflammatory diseases. Their lead product candidate, remestemcel-L (Ryoncil), is in development for acute graft versus host disease (aGVHD) and has been submitted for FDA approval. The company also has other pipeline candidates, including rexlemestrocel-L, targeting chronic heart failure and chronic lower back pain, operating globally from its Australian base.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$3.2B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/MVF\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"MVF\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Monash Ivf Group Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.69\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-38.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Monash IVF Group Limited operates fertility clinics across Australia and New Zealand, providing assisted reproductive technology (ART) services including IVF, IUI, and fertility testing. They also offer complementary gynecological and obstetric services. With a network of clinics, the company serves patients through direct services and partnerships with medical professionals.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$275M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/MVP\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"MVP\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Medical Developments International Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.46\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-17.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Medical Developments International Limited (MVP) is an Australian pharmaceutical company specializing in the development and commercialisation of pain management and respiratory products. Its flagship product is Penthrox (the 'green whistle'), an inhaled fast-acting analgesic for acute pain, distributed across Australia, Europe, and other international markets. The company focuses on expanding its global footprint for Penthrox and developing new product applications.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$55M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/MX1\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"MX1\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Micro-X Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.09\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"45.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Micro-X Limited is an Adelaide-based high-tech company that designs and manufactures ultra-lightweight, mobile X-ray imaging systems. Its core innovation is a proprietary Carbon Nanotube (CNT) X-ray emitter, which enables smaller and lighter devices than traditional systems. The company's flagship product is the 'Rover' mobile X-ray for hospitals, and it is developing new applications for its technology in airport security and pre-hospital stroke diagnosis.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$65M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/MYX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"MYX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Mayne Pharma Group Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"2.70\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-62.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Mayne Pharma Group Limited (ASX: MYX) is an Australian-based specialty pharmaceutical company that develops, manufactures, and commercialises a portfolio of branded and generic pharmaceutical products. Operating primarily in Australia and the United States, the company focuses on therapeutic areas such as women's health and dermatology, leveraging its drug delivery technologies.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$222M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/NC6\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"NC6\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Nanollose Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.07\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"80.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Nanollose Limited (ASX: NC6) is an Australia-based biotechnology company focused on developing novel, sustainable biomaterials. The company operates primarily in Australia and is known for its innovative approach to producing cellulose from organic waste, targeting applications in health care, textiles, and more. Key products include its patented nanocellulose materials for wound care and cosmetic applications.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$23M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/NAN\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"NAN\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Nanosonics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"3.91\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-14.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Nanosonics is a global infection prevention company that develops and commercialises innovative technologies to reduce the risk of cross-contamination in medical settings. Its flagship product, the Trophon2, is an automated system providing high-level disinfection (HLD) for ultrasound probes. The company operates on a 'razor-and-blade' model, selling capital equipment and generating recurring revenue from the sale of associated high-margin consumables.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$1.2B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/NEU\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"NEU\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Neuren Pharmaceuticals Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"13.20\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"10.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Neuren Pharmaceuticals is an Australian biotechnology company developing therapies for rare and debilitating neurological disorders. Its first drug, trofinetide (marketed as DAYBUE™), is approved and sold in the United States for the treatment of Rett syndrome, generating significant royalty revenue. The company is advancing its pipeline candidate, NNZ-2591, through clinical trials for other serious conditions including Phelan-McDermid, Angelman, and Pitt Hopkins syndromes.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$1.9B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/NOX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"NOX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Noxopharm Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.07\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-17.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Noxopharm Limited is a clinical-stage Australian biotechnology company focused on developing novel treatments for cancer. Its core focus is on its proprietary idronoxil (Veyonda®) technology platform, which aims to enhance the effectiveness of standard cancer therapies like chemotherapy and radiotherapy. The company's operations are centered on progressing its drug candidates through preclinical and clinical trials to address unmet needs in oncology.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$19M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/NSB\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"NSB\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Neuroscientific Biopharmaceuticals Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.14\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"278.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Neuroscientific Biopharmaceuticals Ltd (NSB) is an Australian clinical-stage pharmaceutical company focused on developing novel peptide-based drugs for neurological and neurodegenerative disorders. Their lead drug candidate, EmtinB, targets conditions such as Alzheimer's disease, Multiple Sclerosis, and glaucoma, aiming to address significant unmet medical needs. The company is advancing its proprietary therapeutic compounds through various stages of preclinical and clinical development.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$47M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/NTI\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"NTI\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Neurotech International Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-54.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Neurotech International Limited (ASX: NTI) is a clinical-stage biotechnology company focused on developing and commercialising neuro-protective and neuro-modulatory pharmaceuticals. Its lead investigational drug, NTI164, is an orally administered full-spectrum cannabinoid product currently undergoing clinical trials for neurological disorders such as Autism Spectrum Disorder (ASD), Rett Syndrome, and Multiple Sclerosis.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$18M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/NUZ\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"NUZ\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Neurizon Therapeutics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.10\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-23.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Neurizon Therapeutics is a clinical-stage Australian biotechnology company focused on developing novel treatments for neurodegenerative diseases. Its lead candidate, NZ-101, is a first-in-class small molecule inhibitor targeting neuroinflammation and is currently in Phase 2 clinical trials for the treatment of relapsing-remitting Multiple Sclerosis (MS). The company operates primarily from research facilities in Melbourne, Australia.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$65M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/NXS\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"NXS\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Next Science Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.14\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"31.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Next Science Limited (ASX: NXS) is an Australian medical technology company focused on the development and commercialization of patented XBIO™ technology, designed to disrupt bacterial biofilms and reduce the impact of infection. The company offers a range of products for surgical site infection prevention, chronic wound management, and medical device infection control, operating primarily in the United States and expanding globally.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$-1\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/NXN\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"NXN\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Nexsen Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.17\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"0.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Nexsen Limited is a clinical-stage Australian biotechnology company focused on developing novel cell therapies for hard-to-treat solid tumours. Headquartered in Melbourne, its lead candidate, NXN-101, is an autologous CAR-T therapy targeting a novel antigen prevalent in pancreatic and colorectal cancers. The company is currently advancing NXN-101 through a Phase 1a clinical trial to establish safety and tolerability.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$39M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/NYR\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"NYR\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Nyrada Inc.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.82\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"662.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Nyrada Inc. is an Australian-based biotechnology company focused on the development of novel neuroprotectants and cardiovascular therapeutics. The company's lead programs target significant medical needs such as traumatic brain injury, stroke, and certain cardiovascular diseases, with drug candidates in pre-clinical and early clinical development phases. Nyrada operates primarily in the research and development sector, aiming to develop first-in-class treatments.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$225M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/OCA\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"OCA\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Oceania Healthcare Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.68\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"24.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Oceania Healthcare Limited (ASX: OCA) operates healthcare facilities, focusing on aged care and retirement living in New Zealand. With operations primarily in NZ, key services include residential care, retirement villages, and healthcare support. Listed on the ASX since 05/05/2017.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$525M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/OCC\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"OCC\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Orthocell Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.95\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-36.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Orthocell Limited is an Australian regenerative medicine company focused on developing and commercialising products for the repair of soft tissue injuries. The company's key products include Remplir™ (formerly CelGro®), a collagen medical device for nerve and tendon repair, and Ortho-ATI®, a first-in-class cell therapy for treating chronic tendon injuries. Orthocell is transitioning from R\u0026D to commercialisation, with products approved for sale in Australia, Europe, and the United States.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$250M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/OIL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"OIL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Optiscan Imaging Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.09\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-35.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Optiscan Imaging Limited is a Melbourne-based medical technology company pioneering the development of confocal endomicroscopy imaging systems for real-time, in-vivo cellular imaging. Their flagship product, the InVivage® system, acts as a 'digital biopsy' tool, enabling surgeons and clinicians to view tissue at a microscopic level during procedures, primarily for cancer detection and surgical margin assessment. The company is advancing its technology for various applications, including oral cancer, breast cancer, and neurosurgery.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$94M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ONE\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ONE\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Oneview Healthcare Plc\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.29\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-3.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Oneview Healthcare provides a cloud-based Care Experience Platform (CXP) for hospitals and healthcare systems, designed to improve the patient experience and streamline clinical workflows. The platform integrates with existing hospital IT infrastructure to deliver personalised education, entertainment, communication tools, and meal ordering directly to the patient's bedside device. Operating globally with key markets in the US, Australia, and the Middle East, Oneview aims to empower patients and support care teams through its digital solution.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$230M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/OPT\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"OPT\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Opthea Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.60\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"0.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal eye diseases. Its lead product candidate, sozinibercept (OPT-302), is in Phase 3 clinical trials for the treatment of wet age-related macular degeneration (wet AMD) and Diabetic Macular Edema (DME). The company's strategy is to develop sozinibercept as a combination therapy with standard-of-care anti-VEGF-A drugs to achieve superior vision outcomes for patients.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$-1\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/OSX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"OSX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Osteopore Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-55.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Osteopore Limited (ASX: OSX) is a medtech company developing proprietary 3D printed scaffolds for tissue regeneration, focusing on bone repair. Operating in Australia with products under development for global markets, its key product is a bioresorbable scaffold for orthopedic and craniofacial applications. Based in Perth, Western Australia, it leverages local research partnerships.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$5M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/OSL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"OSL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Oncosil Medical Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.72\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-60.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Oncosil Medical Ltd is a medical device company focused on developing and commercialising localised radiation therapies for cancer. Its lead product, the OncoSil™ device, is a targeted brachytherapy treatment for patients with locally advanced, unresectable pancreatic cancer. The company is primarily focused on driving commercial adoption in Europe, where it has CE Mark approval, and pursuing regulatory approval in the United States.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$13M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/PAB\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PAB\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Patrys Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.04\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"16.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Patrys Limited (ASX: PAB) is an Australian clinical-stage biotechnology company focused on developing novel antibody-based therapeutics for cancer. Their lead product candidate, PAT-DX1, is a humanised IgG antibody designed to penetrate the blood-brain barrier and target DNA damage repair pathways in cancer cells, aiming to treat both primary and metastatic brain cancers, as well as other solid tumours.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$20M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/PAR\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PAR\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Paradigm Biopharmaceuticals Limited..\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.30\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-7.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Paradigm Biopharmaceuticals is a late-stage drug development company focused on repurposing the drug pentosan polysulfate sodium (branded as Zilosul®) for treating unmet needs in musculoskeletal disorders. The company's lead program is a pivotal Phase 3 clinical trial investigating Zilosul® as a potential disease-modifying treatment for knee osteoarthritis (OA). Paradigm operates primarily in Australia and the United States, targeting major global pharmaceutical markets.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$130M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/PCK\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PCK\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Painchek Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.23\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-11.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Painchek Ltd (ASX: PCK) is an Australian health technology company that has developed and commercialised the Painchek® app, an AI-powered pain assessment tool. This medical device uses facial recognition and AI to assess and document pain in individuals who cannot reliably verbalise it, primarily targeting people with dementia in aged care and non-verbal children. The company operates in Australia, the UK, New Zealand, and Canada, aiming to address a significant unmet clinical need globally.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$54M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/PEB\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PEB\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Pacific Edge Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.17\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"50.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Pacific Edge Limited (ASX: PEB) is a New Zealand-based healthcare company specialising in the development and commercialisation of non-invasive diagnostic tests for the early detection and management of cancer. Its flagship product suite, Cxbladder, focuses on bladder cancer detection and surveillance, primarily targeting the significant US market alongside New Zealand and other international regions.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$169M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/PER\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PER\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Percheron Therapeutics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-27.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Percheron Therapeutics Limited (ASX: PER) is an Australian clinical-stage biotechnology company focused on developing novel psychedelic medicines for the treatment of various mental health conditions. Its lead program, PER-003, is being advanced for indications such as Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD), aiming to address significant unmet medical needs.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$9M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/PGC\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PGC\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Paragon Care Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.20\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-45.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Paragon Care Limited is a leading provider of medical equipment, devices, and consumables to the health and aged care sectors across Australia and New Zealand. The company operates through several pillars, including diagnostics, medical devices, capital equipment, and services. PGC acts as a key distributor for global manufacturers, offering a diversified portfolio of products to hospitals, medical clinics, and aged care facilities.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$348M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/PIQ\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PIQ\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Proteomics International Laboratories Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.46\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-8.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Proteomics International Laboratories Ltd (ASX: PIQ) is a medical technology company focused on proteomics, the large-scale study of proteins. Its lead product, PromarkerD, is a predictive diagnostic test for diabetic kidney disease, which it is commercialising globally. The company operates from its headquarters in Perth, Western Australia, and is also developing a pipeline of other diagnostic tests for diseases like endometriosis and oesophageal cancer.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$81M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/PKP\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PKP\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Peak Processing Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-10.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Peak Processing Limited (ASX: PKP) is a specialist contract development and manufacturing organisation (CDMO) operating within Australia's life sciences sector. The company provides formulation, processing, and packaging services for therapeutic goods from its TGA-licensed facility. PKP focuses on high-growth niches, particularly medicinal cannabis oils, tinctures, and other novel drug delivery systems for third-party pharmaceutical and biotech clients.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$17M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/PME\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PME\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Pro Medicus Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"164.93\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-17.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Pro Medicus Limited (PME) is an Australian health care technology company focused on diagnostic imaging solutions. Headquartered in Melbourne, it operates predominantly in Australia and internationally, offering products like Xercise, MedMovie, and iMIX, which cater to medical imaging, patient engagement, and imaging data management. Key services include imaging software and related support.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$17.4B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/PTX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PTX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Prescient Therapeutics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.07\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"51.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer therapies. Based in Australia, it focuses on its next-generation CAR-T platform, OmniCAR, designed to enhance control and safety, alongside a pipeline of targeted therapies including PTX-100 for T-cell lymphomas.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$78M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/PYC\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PYC\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Pyc Therapeutics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"1.50\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"22.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Pyc Therapeutics Limited (ASX: PYC) is an Australian clinical-stage biotechnology company focused on developing a new generation of RNA therapeutics to treat blinding eye diseases and neurodevelopmental disorders. Leveraging its proprietary drug delivery platform, PYC aims to deliver RNA drugs into cells to address previously untreatable genetic conditions, operating primarily out of Australia with global ambitions for its pipeline.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$881M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/RAC\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"RAC\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Racura Oncology Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"2.30\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"116.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Ratura Oncology Ltd (ASX: RAC) is an Australian-listed biotechnology company focused on the discovery, development, and commercialization of novel therapeutic candidates for the treatment of various cancers. Operating primarily in the preclinical and clinical trial phases, the company aims to address unmet medical needs within oncology by advancing its pipeline of drug candidates.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$416M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/RAD\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"RAD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Radiopharm Theranostics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-18.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Radiopharm Theranostics Limited (ASX: RAD), listed in November 2021, operates in the Health Care sector focusing on Pharmaceuticals, Biotechnology, and Life Sciences. They are developing targeted theranostic products for cancer treatment, primarily working in Australia with potential for global market expansion. Key products/services include radiopharmaceuticals for both diagnostic imaging and targeted cancer therapy.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$78M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/RCE\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"RCE\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Recce Pharmaceuticals Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.59\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"63.9\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Recce Pharmaceuticals is a clinical-stage biotechnology company developing a new class of synthetic anti-infectives to address the global health problem of antibiotic-resistant superbugs. Headquartered in Australia, its lead product, RECCE® 327, is a broad-spectrum antibiotic being evaluated in clinical trials for serious and life-threatening infections including sepsis and diabetic foot ulcers.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$166M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/REG\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"REG\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Regis Healthcare Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"6.66\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-1.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Regis Healthcare Limited (ASX: REG) is one of Australia's largest providers of residential aged care services. The company operates numerous aged care facilities across Australia, offering a comprehensive range of services including permanent accommodation, dementia care, respite care, and palliative care for the elderly. Regis focuses on delivering high-quality care within a regulated framework.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$2.0B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/RHC\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"RHC\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Ramsay Health Care Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"36.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"5.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Ramsay Health Care Limited is a leading global operator of private hospitals and healthcare facilities. It provides a comprehensive range of medical, surgical, rehabilitation, and mental health services across Australia, Europe (France, UK, Nordics), and Asia. The company focuses on delivering high-quality patient care within its extensive network of hospitals and day surgeries.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$8.2B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/RGT\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"RGT\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Argent Biopharma Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.05\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-68.2\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Argent Biopharma is an Australian clinical-stage biotechnology company focused on developing novel therapies for inflammatory and autoimmune diseases. Its lead drug candidate, ARG-007, is an intravenous therapeutic being developed to treat Chronic Obstructive Pulmonary Disease (COPD) and other significant unmet medical needs. The company is advancing ARG-007 through the pre-clinical and clinical trial process to establish its safety and efficacy.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$5M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/RHY\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"RHY\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Rhythm Biosciences Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.23\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"193.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Rhythm Biosciences Limited (ASX: RHY) is an Australian medical diagnostics company focused on developing and commercialising its lead product, ColoSTAT, a simple blood test for the early detection of colorectal cancer. The company aims to provide a more accessible and non-invasive screening solution globally, primarily targeting markets in Australia, Europe, and the USA.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$57M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/RHT\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"RHT\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Resonance Health Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.05\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"23.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Resonance Health is a medical technology company specializing in the development and delivery of non-invasive medical imaging analysis services. Operating globally, the company's core products include FerriScan® for liver iron concentration measurement and HepaFat-Scan® for liver fat quantification, both utilising MRI data. RHT is increasingly focused on leveraging artificial intelligence (AI) to expand its suite of diagnostic tools for various diseases.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$22M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/RMD\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"RMD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Resmed Inc\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"37.46\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"7.2\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"ResMed Inc (RMD) is a global leader in respiratory therapies and sleep apnea solutions, operating worldwide with a strong presence in Australia. Key products include CPAP (Continuous Positive Airway Pressure) machines like AirSense and AirFit masks. The company is headquartered in San Diego, USA, but listed on the ASX.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$52.0B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/RNV\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"RNV\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Renerve Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.12\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-7.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Renerve Limited (ASX: RNV) is a Australian health care company operating in the equipment and services sector. Specifically, Renerve focuses on developing innovative neuromodulation solutions for chronic pain management, primarily targeting the Australian market with plans for Southeast Asian expansion. Its key product, the NeuroPace System, offers a minimally invasive, implantable device for precise nerve stimulation.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$20M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/RYM\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"RYM\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Ryman Healthcare Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"2.35\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-8.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Ryman Healthcare Limited is a leading New Zealand-based developer and operator of integrated retirement villages, providing independent living, serviced apartments, and comprehensive aged care facilities. The company operates primarily across New Zealand and in Victoria, Australia, catering to the growing demand for quality senior living and care services.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$2.4B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/SDI\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"SDI\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Sdi Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.95\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"9.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Sdi Limited is an Australian-based developer, manufacturer, and marketer of specialist dental materials for the global professional dental industry. Headquartered in Victoria, the company exports its products to over 100 countries. Its core product lines include restorative materials (composites, amalgams), adhesives, and aesthetic products, most notably the 'Pola' brand of tooth whitening systems.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$114M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/SHG\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"SHG\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Singular Health Group Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.23\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-4.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Singular Health Group Ltd develops cutting-edge 3D medical visualisation technology, primarily through its Volumetric Rendering Platform (VRP). This platform converts traditional 2D medical scans into interactive 3D anatomical models, designed to improve surgical planning, patient education, and implant design within the health care sector globally, with a focus on markets like Australia and the USA.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$74M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/SHL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"SHL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Sonic Healthcare Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"22.57\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-12.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Sonic Healthcare is a leading global medical diagnostics company, providing laboratory medicine, pathology, and radiology services. It operates in over eight countries, including Australia, the USA, and Germany, serving clinicians, hospitals, and medical centres with a comprehensive range of diagnostic testing and imaging.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$11.2B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/SIG\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"SIG\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Sigma Healthcare Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"3.16\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"9.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Sigma Healthcare Limited is a leading Australian healthcare company, primarily focused on the wholesale distribution of pharmaceutical goods and medical consumables. It supports a large network of community pharmacies across Australia under brands such as Amcal, Guardian, and Discount Drug Stores. The company is currently undergoing a transformative proposed merger with Chemist Warehouse Group, aiming to create a vertically integrated pharmacy and distribution powerhouse.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$36.5B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/SLD\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"SLD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Saluda Medical, Inc.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"1.21\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-2.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Saluda Medical, Inc. (ASX: SLD) operates in the Health Care Equipment \u0026 Services sector, specifically developing and commercializing next-generation spinal cord stimulation (SCS) technologies in Australia and internationally. Key products include the Saluda Pulse Generators with proprietary software for personalized pain management. The company is headquartered in Australia with primary operations in the APAC region.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$315M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/SNZ\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"SNZ\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Summerset Group Holdings Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"9.70\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-4.2\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Summerset Group Holdings Limited operates retirement villages and aged care facilities, primarily across New Zealand and Australia. Its services include independent living, assisted living, and dementia care. SNZ focuses on senior housing solutions with a portfolio of over 5,000 homes.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$2.4B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/SNT\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"SNT\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Syntara Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.03\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-55.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Syntara Limited is a clinical-stage Australian biotechnology company developing drugs for diseases involving fibrosis and inflammation. Its lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently in a Phase 2 clinical trial for the bone marrow cancer myelofibrosis. The company is also exploring its drug candidates for other indications, including liver and pancreatic cancer.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$56M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/SOM\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"SOM\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Somnomed Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.64\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"14.9\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Somnomed Limited (ASX: SOM) is a healthcare equipment company focused on oral appliance therapy for the treatment of sleep disorders, primarily obstructive sleep apnea (OSA). Operating predominantly in Australia and with international presence, its key products include the mandibular advancement devices (MADs) like the SomnoMed ACTIVATETM and the SomnoMed AIRVTM. These devices are custom-made for each patient to advance the jaw, keeping the airway open during sleep.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$143M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/SPL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"SPL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Starpharma Holdings Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.40\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"325.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Starpharma Holdings Limited (SPL) is an Australian biotech company specializing in pharmaceuticals and life sciences. Headquartered in Melbourne, SPL operates globally, focusing on drug delivery technologies, with its lead product being Dendrimers, particularly the proprietary DuraGel technology for enhancing drug efficacy and safety. Key products include clinical-stage oncology and infectious disease treatments.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$172M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/TD1\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"TD1\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Tali Digital Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.05\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-48.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Tali Digital Limited develops and commercialises digital therapeutics aimed at assessing and improving cognitive function, specifically attention, in early childhood. The company's key products are TALI Detect, a game-based assessment tool, and TALI Train, a digital attention training program, both targeting neurodevelopmental conditions like ADHD and autism. TD1 primarily operates in the Australian market but seeks global partnerships for expansion.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$2M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/TLX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"TLX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Telix Pharmaceuticals Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"10.13\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-61.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Telix Pharmaceuticals is an Australian-based, global biopharmaceutical company focused on developing and commercialising radiopharmaceuticals for cancer diagnosis and treatment. Its lead commercial product, Illuccix, is a prostate cancer imaging agent generating significant revenue primarily in the United States and Europe. The company is advancing a deep pipeline of 'theranostic' candidates designed to both image and treat cancers, with a key focus on prostate and kidney cancer.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$3.4B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/TRJ\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"TRJ\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Trajan Group Holdings Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.67\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-21.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Trajan Group Holdings Limited (ASX: TRJ) is a global developer and manufacturer of analytical and life science products and solutions, with a focus on precision measurement devices and workflows. The company provides specialized components, automation tools, and integrated solutions primarily for the global analytical and healthcare sectors, including chromatography consumables and liquid handling systems. Operating internationally, Trajan aims to enhance the accuracy and efficiency of scientific analysis and personalized healthcare.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$102M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/TRI\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"TRI\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Trivarx Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"40.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Trivarx Ltd is an Australian medical technology company developing its proprietary 'Cardi-Dx' point-of-care diagnostic platform. The device is designed for the rapid detection of key cardiac biomarkers from a single drop of blood, targeting the early and accurate diagnosis of acute cardiac events in emergency departments and clinics. The company is currently advancing the Cardi-Dx system through clinical trials and regulatory approval pathways in Australia and Europe.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$22M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/TRU\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"TRU\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Truscreen Group Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-44.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Truscreen Group Limited (ASX: TRU) develops, manufactures, and sells the TruScreen device, an optical and digital cerviscope for real-time, non-invasive cervical cancer screening. The technology aims to provide immediate, accurate results at the point of care, addressing limitations of traditional Pap smears and HPV tests. Truscreen primarily operates in key markets such as China, Vietnam, Mexico, and other developing nations.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$11M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/TRP\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"TRP\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Tissue Repair Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.20\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-22.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Tissue Repair Ltd is an Australian clinical-stage biopharmaceutical company focused on developing advanced wound healing solutions. The company's core technology is a unique glucan polymer, with its lead product, Glucoprime (TR-987), being a topical gel designed to treat chronic wounds and post-surgical scarring. TRP's strategy is to progress its assets through clinical trials to demonstrate safety and efficacy before seeking commercialisation partnerships.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$12M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/TTX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"TTX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Tetratherix Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"3.80\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-24.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Tetratherix Limited (ASX: TTX) is an Australian biotechnology company focused on the discovery and development of novel therapeutic candidates for underserved medical conditions, with a primary focus on oncology, immunology, or rare diseases. Operating from its research facilities in Australia, the company leverages advanced drug discovery platforms to progress its proprietary pipeline from pre-clinical stages towards human clinical trials.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$205M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/UBI\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"UBI\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Universal Biosensors Inc.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-79.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Universal Biosensors Inc. (ASX: UBI) develops point-of-care diagnostic and monitoring systems for biosensors. Primarily operating in Australia and targeting global healthcare markets, its key products are based on its proprietary biosensor technology for glucose and other biomarker detections. UBI partners with international pharmaceutical companies for co-development and commercialization.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$-1\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/UCM\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"UCM\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Uscom Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-60.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Uscom Limited (UCM) is an Australian medical device company that develops, manufactures, and markets non-invasive cardiovascular and pulmonary diagnostic equipment. Its key products include the USCOM 1A for advanced cardiac output monitoring, Uscom BP+ for central blood pressure, and SpiroSonic digital ultrasonic spirometers for respiratory diagnostics, distributed globally to hospitals and clinics.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$-1\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/VBS\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"VBS\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Vectus Biosystems Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.14\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"77.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Vectus Biosystems Limited (ASX: VBS) is an Australian biotechnology company dedicated to the discovery and development of novel small molecule drugs for fibrotic diseases. Their primary focus is on conditions like heart failure and kidney fibrosis, leveraging their expertise in the Renin-Angiotensin-Aldosterone System (RAAS) to progress proprietary drug candidates through pre-clinical and early clinical stages within Australia.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$6M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/VFX\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"VFX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Visionflex Group Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.09\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-37.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Visionflex Group Limited (ASX: VFX) is an Australian medical technology company developing and commercialising innovative telehealth solutions. Their core offering includes the Visionflex telehealth platform and the ProEX Series of integrated medical devices, enabling remote diagnostic examinations and consultations. The company aims to facilitate high-quality healthcare delivery across diverse settings, from hospitals and aged care facilities to remote communities and defence operations.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$8M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/VFY\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"VFY\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Vitrafy Life Sciences Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"1.65\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"37.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Vitrafy Life Sciences Limited (ASX: VFY), listed since November 26, 2024, is an Australian biotechnology company focused on developing innovative therapeutics for underserved diseases. Operating primarily in Australia with potential for global product reach, their key product/service involves researching and developing novel biologic treatments, currently in pre-clinical stages. Specific focus areas include oncology and rare genetic disorders.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$103M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/VHL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"VHL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Vitasora Health Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-48.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Vitasora Health Limited (VHL) is an Australian healthcare company focused on developing innovative medical devices and diagnostics within the Health Care Equipment \u0026 Services sector. Operating primarily in Australia, with potential regional expansion plans, VHL's key products include specialized diagnostic tools for cardiology and respiratory diseases. As of its last update, the company has been listed on the ASX since 2000, indicating a long-standing presence in the market.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$41M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/VIT\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"VIT\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Vitura Health Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.06\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-28.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Vitura Health Limited (ASX: VIT) operates in Australia, specializing in sleep disorder diagnostics and treatments. Specifically, they focus on respiratory and sleep care services, offering solutions like sleep diagnostics and therapy management across their clinics. With a presence in key Australian urban centers, their primary services include at-home sleep testing and personalized treatment plans.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$38M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/VLS\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"VLS\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Vita Life Sciences Limited..\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"2.70\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"42.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Vita Life Sciences Limited (VLS) is an Australian-based company specializing in the manufacture, distribution, and marketing of a diverse range of vitamins, minerals, and dietary supplements. Operating primarily across Australia and Southeast Asia, the company focuses on health and wellness products under well-known brands such as VitaHealth, VitaScience, and Herbs of Gold. Their portfolio includes therapeutic supplements designed to support general health, immune function, and specific health concerns.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$155M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ZLD\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ZLD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Zelira Therapeutics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.62\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"34.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Zelira Therapeutics Limited is a global biopharmaceutical company focused on the research, development, and commercialization of cannabinoid-based medicines. Operating primarily in Australia and the US, the company's key products include ZENIVOL® for chronic insomnia and HOPE® for symptoms related to Autism Spectrum Disorder. Zelira pursues a strategy of clinical validation to develop proprietary IP for licensing and sale.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$7M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}]]}]]}]]}]],null],null]},[\"$\",\"$L7\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"sectors\",\"children\",\"$8\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L9\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[\"$\",\"$L7\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"sectors\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L9\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"__variable_6d343d __variable_49a339\",\"children\":[[\"$\",\"head\",null,{\"children\":[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/logo.svg\",\"type\":\"image/svg+xml\"}]}],[\"$\",\"body\",null,{\"className\":\"min-h-screen bg-ink-900 text-slate-100\",\"children\":[\"$\",\"div\",null,{\"className\":\"grid-glow min-h-screen\",\"children\":[[\"$\",\"header\",null,{\"className\":\"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8\",\"children\":[[\"$\",\"$L6\",null,{\"href\":\"/\",\"className\":\"flex items-center gap-3\",\"children\":[[\"$\",\"$La\",null,{\"src\":\"/logo.svg\",\"alt\":\"ASX Desk\",\"width\":140,\"height\":40,\"className\":\"h-10 w-auto\",\"priority\":true}],[\"$\",\"span\",null,{\"className\":\"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline\",\"children\":\"Research Terminal\"}]]}],[\"$\",\"nav\",null,{\"className\":\"hidden items-center gap-6 text-sm text-slate-300 md:flex\",\"children\":[[\"$\",\"$L6\",\"/\",{\"href\":\"/\",\"className\":\"transition hover:text-white\",\"children\":\"Home\"}],[\"$\",\"$L6\",\"/screener\",{\"href\":\"/screener\",\"className\":\"transition hover:text-white\",\"children\":\"Screener\"}],[\"$\",\"$L6\",\"/sectors/materials\",{\"href\":\"/sectors/materials\",\"className\":\"transition hover:text-white\",\"children\":\"Sectors\"}],[\"$\",\"$L6\",\"/news\",{\"href\":\"/news\",\"className\":\"transition hover:text-white\",\"children\":\"News\"}],[\"$\",\"$L6\",\"/compare/BHP-vs-RIO\",{\"href\":\"/compare/BHP-vs-RIO\",\"className\":\"transition hover:text-white\",\"children\":\"Compare\"}],[\"$\",\"$L6\",\"/about\",{\"href\":\"/about\",\"className\":\"transition hover:text-white\",\"children\":\"About\"}]]}],[\"$\",\"div\",null,{\"className\":\"hidden items-center gap-3 md:flex\",\"children\":[[\"$\",\"$Lb\",null,{}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20\",\"children\":\"Premium Research\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400\",\"children\":\"Open Account\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex-1\",\"children\":[\"$\",\"$Lb\",null,{}]}],[\"$\",\"$L6\",null,{\"href\":\"/screener\",\"className\":\"shrink-0 text-xs text-blue-300\",\"children\":\"Screener\"}]]}]]}],[\"$\",\"main\",null,{\"className\":\"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8\",\"children\":[\"$\",\"$L7\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L9\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[\"$\",\"div\",null,{\"className\":\"flex min-h-[60vh] flex-col items-center justify-center text-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"404\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":\"Page not found\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"We couldn't locate that ASX page. Try searching a ticker or visit the homepage.\"}],[\"$\",\"$L6\",null,{\"href\":\"/\",\"className\":\"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Back to Home\"}]]}],\"notFoundStyles\":[],\"styles\":null}]}],[\"$\",\"footer\",null,{\"className\":\"border-t border-white/10 bg-ink-800/60\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"ASX Desk\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex gap-3\",\"children\":[[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300\",\"children\":\"Download Media Kit\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-2 gap-6 text-sm text-slate-400\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Platform\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/screener\",\"className\":\"hover:text-white\",\"children\":\"Screener\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/news\",\"className\":\"hover:text-white\",\"children\":\"News \u0026 Commentary\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/about\",\"className\":\"hover:text-white\",\"children\":\"About\"}]}]]}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Sectors\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/sectors/materials\",\"className\":\"hover:text-white\",\"children\":\"Materials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/sectors/financials\",\"className\":\"hover:text-white\",\"children\":\"Financials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/sectors/health care\",\"className\":\"hover:text-white\",\"children\":\"Health Care\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/sectors/information technology\",\"className\":\"hover:text-white\",\"children\":\"Information Tech\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/sectors/energy\",\"className\":\"hover:text-white\",\"children\":\"Energy\"}]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h4\",null,{\"className\":\"font-semibold\",\"children\":\"Weekly Alpha Briefing\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-sm text-slate-400\",\"children\":\"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex flex-col gap-3 sm:flex-row\",\"children\":[[\"$\",\"input\",null,{\"type\":\"email\",\"placeholder\":\"you@example.com\",\"className\":\"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Subscribe\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-xs text-slate-500\",\"children\":\"By subscribing you agree to receive marketing updates. Unsubscribe anytime.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"border-t border-white/10 py-6 text-center text-xs text-slate-500\",\"children\":[\"$\",\"p\",null,{\"children\":\"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.\"}]}]]}]]}]}]]}],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$Lc\"],\"globalErrorComponent\":\"$d\",\"missingSlots\":\"$We\"}]]\n"])</script><script>self.__next_f.push([1,"c:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"health care sector stocks on the ASX | trends \u0026 top performers | ASX Desk\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"Explore ASX health care stocks, sector trends, and leading performers with AI-generated insights.\"}],[\"$\",\"link\",\"4\",{\"rel\":\"canonical\",\"href\":\"https://asxdesk.com/sectors/health%20care/\"}],[\"$\",\"meta\",\"5\",{\"property\":\"og:title\",\"content\":\"health care sector stocks on the ASX | trends \u0026 top performers\"}],[\"$\",\"meta\",\"6\",{\"property\":\"og:description\",\"content\":\"Explore ASX health care stocks, sector trends, and leading performers with AI-generated insights.\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:url\",\"content\":\"https://asxdesk.com/sectors/health%20care/\"}],[\"$\",\"meta\",\"8\",{\"name\":\"twitter:card\",\"content\":\"summary_large_image\"}],[\"$\",\"meta\",\"9\",{\"name\":\"twitter:title\",\"content\":\"ASX Desk\"}],[\"$\",\"meta\",\"10\",{\"name\":\"twitter:description\",\"content\":\"Australia's AI-powered ASX stock research platform delivering instant analysis, sector insights, and SEO-optimized company profiles.\"}],[\"$\",\"meta\",\"11\",{\"name\":\"next-size-adjust\"}]]\n5:null\n"])</script></body></html>